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Skeletal muscle related diseases cause loss and weakness in the muscle and affect the 
quality of life of the patients. Although skeletal muscle tissue can regenerate when the damage is 
small, a patient must receive a surgery when the volumetric loss is too large. Skeletal muscle tissue 
engineering aims to recapitulate the physiology and function of the natural muscle. The engineered 
tissue holds potential as a transplantable material that can help regeneration in vivo. 
In this thesis, we used different methodologies to recapitulate the natural skeletal muscle 
and enhance muscle development. The first part of the thesis uses physical approach to engineer 
functional skeletal muscle. A grooved substrate with controlled width was used to promote 
myogenic differentiation and enhance muscle maturity. After the mature muscle was generated, 
we cultured neural stem cells and let them innervate into the skeletal muscle to form a neuron-
muscle interface to finally engineer a functional skeletal muscle (Chapter 3). The next study 
focuses on chemically stimulating the skeletal myoblasts to express more gap junction proteins 
and prolong the expression time. After confirming the genetic changes occurring in the muscle 
cells, we assembled a pump-bot device with the pre-stimulated skeletal muscle tissue engineered 
in a 3D ring. We compared how the fluid movement in the pump-bot was changed when the 
myoblasts had been chemically stimulated (Chapter 4). Lastly, we biologically modified the 
skeletal myoblasts to express gap junction proteins in myotubes (Chapter 5). We delivered 
connexin genes to the skeletal myoblasts. We examined how the presence of connexin in the cells 
contributes to myogenic differentiation and muscle development. Overall, the studies herein will 
be useful to engineer skeletal muscle for biomedical uses such as developing platforms for in vitro 
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CHAPTER 1: INTRODUCTION 
1.1 Motivation 
In the field of tissue engineering, understanding how cells behave and respond to a 
controlled stimulus is crucial. Generally, different types of cells require distinct stiffness, 
topography, chemical stimulus to become a functional tissue. Researchers utilize a combination of 
biochemical as well as biophysical stimuli to provide a controlled environment for the cells. The 
main hypothesis of this dissertation is that microenvironment can control cellular emergence which 
may result in physiological and functional change of the engineered tissue. The microenvironments 
can be modulated by changing the physical, chemical, and biological cues of the surroundings. As 
we have thorough understanding of the interface of cells and materials, we can build functional 
tissues which can be used for various biomedical applications such as drug screening, 
transplantation, or building biological machinery. 
 
1.2. Project Overview 
 This thesis seeks to enhance the quality of engineered muscle by controlling the maturity 
and functionality of the skeletal muscle tissue. To do so, different methodologies were employed 
to modulate the microenvironment of the skeletal muscle. For example, substrates with controlled 
topography were used to promote skeletal muscle maturity. A graphene-based nanomaterial was 
incorporated into the skeletal myoblasts to investigate the biological changes which resulted in 
myotube maturity. Furthermore, the myoblast cells were genetically modified to enhance the 
maturity and function after differentiation. 
In chapter 3, we modulated the physical microenvironment. We used substrates with 
grooved topography with controlled width to promote skeletal myoblast maturation and neural 
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innervation. We examined if the groove size similar to the extracellular matrices or the myofibril 
enhanced maturation of the myotubes. Then, we studied how the maturation and alignment of the 
myotubes aid differentiation of the neural stem cells to become motor neuron progenitor cells and, 
subsequently, innervate into the skeletal myotubes. Furthermore, we tested the functionality of the 
engineered neuron-muscle interface by treating the tissue with a neural stimulator glutamate, and 
an antagonist, curare. 
In chapter 4, we provided chemical cues to the skeletal myoblasts. We treated the skeletal 
myoblasts with reduced graphene oxide and explored how the material interacts with the skeletal 
myoblasts to enhance muscle maturation. In particular, we examined if the gap junction protein, 
connexin 43, expression is extended upon treating reduced graphene oxide and this event can 
promote myogenic differentiation of the myoblasts. In the end, we used the reduced graphene 
oxide treated skeletal muscles to engineer 3D muscle ring and tested with a pump-bot device. 
In chapter 5, biological approach to genetically modify the cells was used to improve the 
quality of engineered muscle. After transfecting the myoblasts to express connexins, we focused 
on exploring the role of the gap junction proteins on myogenesis and how they can contribute to 
forming mature myotubes. We used myoblasts that continuously express different types of gap 
junction proteins after differentiation.  
Ultimately, the results from these studies will be useful in engineering functional skeletal 
muscle tissue with better quality. The findings will broadly benefit developing drug screening 
platforms for skeletal muscle diseases, building biological actuators, and regeneration therapies. 
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CHAPTER 2: LITERATURE REVIEW ON SKELETAL MUSCLE TISSUE 
ENGINEERING 
2.1 Skeletal Muscle Tissue Engineering 
Skeletal muscle related diseases including muscular dystrophy, atrophy, myopathy and 
traumatic injuries cause loss and weakness in the muscle. Since muscle comprise approximately 
40% of the body mass and is responsible for locomotion, skeletal muscle injury may significantly 
affect the quality of life of the patients1. Although skeletal muscle can self-regenerate up to a 
certain threshold, the tissue cannot fully recover the function beyond this point. Generally, if the 
volumetric muscle loss exceeds 20%, the patient needs to go through a surgical procedure or a 
physical therapy.2  
During the surgical procedure, an autologous muscle is transferred from a donor site to the 
injured site. Latissimus dorsi muscle and gracilis muscle are the two largest sources used for 
autonomous transplantation. In addition, physical therapy is often performed after the surgery to 
prevent additional muscle loss around the injured site. However, the reconstruction surgery often 
results in failure in grafting, morbidity around the donor site, and insufficient neuron innervation. 
Furthermore, physical therapy alone cannot regenerate the skeletal muscle and restore volumetric 
muscle loss completely.3 Another strategy to inject muscle cells ex vivo exists but this method also 
has limitations due to poor cell survival, migration and immune response.3 
Skeletal muscle tissue engineering targets to recapitulate the structure and function of the 
natural tissue. After successfully engineering the skeletal muscle tissue, the construct holds 
potential as a transplantable material to an in vivo model, or an in vitro platform that can screen 
drugs. There are mainly two approaches to perform skeletal muscle tissue engineering. First, to 
develop mature myotubes and assemble a functional tissue in vitro. After the tissue is fully 
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developed, the construct can be transplanted at the injured site. However, innervation of the 
neurons into the skeletal muscle after transplantation, restoration of the physically relevant 
contraction force, vascularization to maintain viability of the tissue, and construction of a highly 
dense fiber bundle still remain as challenge.4-5 On the other hand, the other strategy is to transplant 
cells and supporting those cells to undergo myogenesis in vivo. The purpose of this method is to 
provide cues to the host cells to undergo endogenous regeneration. A supportive material to 
provide a niche is often used together in this case. This strategy, however, also holds limitation 
due to immune response of the host and loss in cell number after transplantation.6 Thus, it is 
important to balance each factor to maximize the regeneration efficacy after transplanting the 
engineered skeletal muscle tissue.  
 
2.2 Importance of the cell-material interface  
 The choice of cell for skeletal muscle tissue engineering requires consideration of several 
characteristics. First, the cells should be accessible and should maintain their growth and 
differentiation well in vitro. The cells sources should also hold potential to develop into 
physiologically and functionally relevant muscle tissue.7 A large range of cells fall into the 
category including satellite cells, muscle stem cells, myoblasts, mesenchymal stem cells, induced 
pluripotent stem cells, embryonic stem cells, and pericytes.7-8 Systematic or local delivery of these 
cells allows the cells to develop into myofibers and aid regeneration at the injured site.9-10 This, 
however, may result in loss of cells during delivery. Furthermore, the cells to differentiate and 
develop into mature muscle takes a long time. Thus, to potentiate the myogenic potential of the 
cells and improve the function after transplantation, researchers have focused on investigating the 
cell-material interface.  
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 Skeletal muscle tissue engineering utilizes a broad range of biomaterials that can 
overcome current limitations. These biomaterials allow the cells to form functional and self-
regenerative skeletal muscles, innervated and vascularized to closely recapitulate the natural 
skeletal muscle. For example, numerous blood vessels supply nutrient to the skeletal muscle 
following the connective tissues and each muscle fiber is innervated by motor neurons that 
stimulate the skeletal muscle to contract.11-12 In fact, a highly porous poly-L-lactic acid (PLLA) 
and polylactic-glycolic acid (PLGA) substrate was used for co-culturing myoblasts, embryonic 
fibroblasts, and endothelial cells.13 The skeletal muscle tissue engineered with the endothelial cells 
showed improved blood perfusion and survival rate after being transplanted to an in vivo animal 
model.  
 To maximize the effects of biomaterials for skeletal muscle tissue engineering, the 
platform should be developed with appropriate physical, chemical, and biological cues. These cues 
also must support myoblast proliferation, differentiation, maturation, and health. In the following 
sections, different approaches to provide each cue to the skeletal myoblasts are discussed in more 
details.  
 
2.3 Physical Approach 
 Physical cues of the material are important factors in tissue development and can control 
cell function and fate. There are different methods to manipulate the physical property of material 
such as changing the geometry, stiffness, or topography of the substrate.14 To physically 
manipulate the microenvironment, we must first understand the physiological characteristic of the 
skeletal muscle. Skeletal muscles consist of multiple bundles of muscle fibers, comprised of 
multinucleated myotubes.15 These fiber bundles are surrounded by connective tissues which 
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supports the uniaxial shape and longitudinal movement. The actin and myosin in the bundles are 
pulled along the aligned tissue. Thus, the architecture of the skeletal muscle directly relates to the 
contraction of the skeletal muscle.16 Thus, providing an appropriate physical stimulus to the 
skeletal muscle cells is advantageous to create a skeletal muscle tissue with better function.15  
 Linear topography is known to facilitate skeletal myoblasts to uniaxially align and form 
myotubes similar to the natural skeletal muscle.17-19 As mentioned above, the alignment directly 
influences the functionality of the tissue in vivo, thus, this feature is considered significant for in 
vitro muscle tissue engineering. For example, the skeletal muscle tissue engineered with pre-
aligned myotubes generated 2-fold increased contraction force compared to the tissue engineered 
with randomly oriented myotubes.20 The myoblasts were pre-cultured on a micropatterned 
polydimethylsiloxane pattern and the muscle layer was transferred on a fibrin gel where the cells 
self-organized into a 3D muscle construct.  
 Substrate stiffness also plays a significant role in skeletal muscle development. The 
modulus varies as the muscle develops, but the Young’s modulus of the skeletal muscle tissue is 
known to be between 10-20 kPa.21-22 In fact, substrate stiffness around 10-20 kPa has shown to 
facilitate myogenic differentiation and maturation of myotubes of the skeletal myoblasts as well 
as mesenchymal stem cells.14, 23 However, there are also controversial reports that stiffer substrates 
enhance myotube striation. 
In addition, electrical stimulus is another commonly used method to physically manipulate 
the microenvironment.24-25 This approach is widely used to both stimulate myoblasts during 
differentiation and after myotube formation. Interestingly, stimulating the myoblasts during 
differentiation allows more mature myotube formation during myogenesis showing better 
multinucleation and more number of myotubes.26 Furthermore, when myotubes are stimulated 
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electrically, they can produce higher force.27 Mechanical stimulation such as exercise is another 
way to provide physical cues to the engineered skeletal muscle. This strategy is similar to the 
physical therapy performed with the patients after a muscle transplantation surgery.28-29  
 Some studies use multiple features to physically stimulate the skeletal myoblasts. For 
example, a micropatterned gelatin hydrogel can enhance more mature myotube formation and long 
term culture compared to the polydimethylsiloxane substrate, a stiffer substrate, without the 
grooves.30 The myotubes formed on the micropatterned gelatin hydrogels formed thicker, longer 
myotubes with better striation after 3 weeks of differentiation.  
 In conclusion, various methods are available to provide physical cues for the skeletal 
myoblasts from changing the property of the material to mechanically or electrically stimulating 
the cells.  
 
2.4 Chemical Approach 
 Together with the physical cues, the extracellular matrix (ECM) provides cells with a wide 
range of chemical cues that modulates the morphology, adhesion, proliferation, differentiation, 
and apoptosis.31-32 For instance, ECM holds adhesion proteins that support cell adhesion including 
fibronectin, collagen, vitronectin, and laminin.31 Usually, the cellular response to these chemical 
cues is studied by immobilizing these proteins on a substrate.33 In skeletal muscle, collagen is the 
major ECM protein which preserves 10% of the total muscle mass.34 Collagen type I and III are 
predominant among the many types. Proteoglycans are also present in the connective tissue and 
they interact with the collagen to maintain the structure and organization of the matrix. In addition, 
glycoproteins such as laminins, integrins, and fibronectins link type IV collagen in the basement 
membrane. Some matrix remodeling enzymes such as matrix metalloprotease (MMP) also exists. 
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The secreted MMPs degrade collagen, fibronectin, proteoglycans, and laminins to remodel and 
regulate skeletal muscle function and development. The membrane bound MMPs are responsible 
for the proteolytic functions near the cell surface.  
 The adhesion proteins, mentioned above, mediate cellular attachment by integrin, a 
transmembrane receptor protein. This protein family mediate both cell-matrix and cell-cell 
interaction in skeletal muscle.35-36 Particularly, the integrins helps the myoblasts to migrate and 
fuse together during myogenesis. In addition, disruption in the integrin-mediated adhesion in 
skeletal muscle cause myopathy.37 Thus, chemical modification of the substrate or cells using the 
tripeptide sequence, arginylglycylaspartic acid (RGD), is widely used to investigate the role of the 
adhesion proteins in skeletal muscle. This sequence is present in fibronectin, vitronectin, 
fibrinogen, laminin and collagen, dominant ECM proteins in myoblasts.38 The most commonly 
used method to introduce this chemical cue to the myoblast is by manipulating the substrate with 
the RGD sequence. Immobilization of the RGD-containing peptide on a poly-L-lysine and poly-
L-glutamic acid substrate promoted myogenic differentiation by showing increased fusion index, 
striation, and myogenic positive nuclei.39  
 Moreover, the chemical composition of the ECM is significant for skeletal muscle 
differentiation and myogenesis when using multiple chemical cues to engineer skeletal muscle.40 
Previously, it was reported that the composition of the collagen I, fibrin and Matrigel change the 
myotube diameter, length and force generation. Matrigel is basement membrane which contains 
ECM proteins such as collagen IV, laminin, etactin, and growth factors including transforming 
growth factor beta, epidermal growth factor, insulin-like growth factor 1, and basic fibroblast 
growth factor.41 These components promote myogenic differentiation by providing structurally 
organized environment and various myogenesis stimulating signals. Thus, higher Matrigel 
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concentration yielded a densely packed skeletal muscle fiber and larger myotube.40 The 
intracellular calcium transients was also higher when the muscle fiber was engineered with higher 
Matrigel concentration. 
Other growth factors or small molecules secreted from the surroundings also regulate 
skeletal muscle formation. Insulin like growth factor (IGF)-1 is a growth hormone that primarily 
works to promote growth and differentiation of the skeletal muscle via autocrine and paracrine 
mechanisms.42 In the in vivo system, the IGF-1 also mediates muscle regeneration after damage 
and is related to the measures of muscular endurance. Thus, IGF-1 is a popularly used growth 
hormone for skeletal muscle tissue engineering. The pathway of IGF-1 affects skeletal muscle 
growth by protein synthesis and degradation. Once IGF-1 binds to the transmembrane protein IGF-
1 receptor, the PI3K/Akt pathway is activated.43 This activation results in hypertrophy and 
inhibition of the key ubiquitin ligase.  
 To successfully guide innervation of motor neurons, agrin, an acetylcholine receptor 
cluster inducing factor, is often incorporated into the culture system. Agrin is trophic factor 
released from the motor neurons and it stimulates phosphorylation of the muscle specific kinase 
(MuSK).44-45 This event localizes acetylcholine receptor (AchR) to the synaptic sites and aids 
neuromuscular junction formation. Due to the importance of neural innervation in functional 
muscle engineering, agrin has been widely used to promote neuromuscular junction. An agrin 
treated C2C12 myoblasts were shown to express more acetylcholine receptors and promote a 
greater number of neuromuscular junction formation as well as enhanced blood vessels.  
 As such, controlled chemical cues provided to the niche will promote growth, migration, 
and differentiation of the myoblasts. With necessary ECM protein present on the environment and 
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soluble growth factors present in the medium, the engineered skeletal muscles will show better 
maturity and function more actively.  
 
2.5 Biological Approach 
 Delivering genetical materials into the cells is a widely used method to biologically 
manipulate the microenvironment. Gene therapy generates a therapeutic effect by correcting the 
diseased gene in cell or introduce new function.46-47 This technique holds promising potential 
because it can possibly be used to correcting inherited genetic disorders as well as acquired 
diseases. Transfection is a method used for gene therapy to introduce foreign nucleic acid to 
genetically modify the cells.48 The engineered cell can express multiple phenotypic characteristics 
or functions depending on the delivered gene. The purpose of gene delivery is mainly to study the 
regulatory function of specific gene and investigate the protein product.  
 To enhance muscle function, researchers have tried to activate the signaling pathways 
involved in myogenesis and muscle development. For instance, IGF-1 gene was transduced into 
the C2C12 skeletal myoblasts to enhance the contractile force.49 A retroviral vector was used to 
deliver IGF-1 gene to the C2C12 cells, which consequently enhanced growth and differentiation 
of the myoblasts. The myotubes formed with the genetically engineered myoblasts showed 
increase in myotube width, myotube area, muscle creatine kinase activity, and contractile force.  
 After a skeletal muscle tissue is formed in vitro, enough nutrient and oxygen must be 
supplied to the myotubes to maintain the viability and function. This is more important when the 
tissue is engineered in 3D form since the center part often goes through necrosis or apoptosis due 
to insufficient nutrient supply.50 B-cell lymphoma 2 (BCL-2) protein is an apoptosis regulator that 
inhibits the mitochondrial dependent cell death.51 Based on this fact, BCL-2 gene was transferred 
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to C2C12 myoblasts with retroviral vector to investigate the function of the engineered muscle 
under stressed conditions.52 The skeletal myotube bundles formed with BCL-2 transfected C2C12 
cells allowed the myotubes to form a densely bundled structure with higher viability. However, 
the engineered muscle bundles without BCL-2 overexpression showed cell death at the central 
region. Another study delivered both IGF-1 and BCL-2 to the C2C12 myoblasts to improve force 
production while minimizing cell apoptosis and necrosis.53 In this study, the myotubes were further 
stimulated electrically to synergistically improve the force production.  
 Sometimes, genes that does not directly enhance myogenesis, but aids engraftment or 
migration are used to modify the myoblasts. Matrix metalloproteinase type 1 (MMP 1) is a well-
known collagen-digesting enzyme. This gene was transfected to the myoblasts to eliminate scar 
tissue formation and enhance regeneration after transplantation.54-56 The transfected myoblasts 
showed enhanced myogenic differentiation yielding myotubes with higher fusion index. More 
importantly, the transplanted MMP1 expressing myoblasts improved migration of the cells to the 
injured site and engraftment of the transplanted cells to the host tissue.  
 As mentioned in the previous section, agrin is secreted by the pre-synaptic axon terminals 
of the neuromuscular junction and this induce AchR aggregation at the post synaptic region. To 
investigate the effect of agrin at the post-synaptic muscle, myoblasts were transfected with gene 
that encodes agrin.45  
 To this end, modulating biological cues is useful to study the effect and function of various 
genes. Particularly, gene transfection could generate a variety of myoblasts with enhanced survival 
rate, differentiation efficiency, myogenesis, or functionality. 
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2.6. Summary and Future Perspectives 
 This review highlights the potential usage of skeletal muscle tissue engineering in clinical 
and laboratory applications. To successfully reconstruct a skeletal muscle tissue in vitro, there 
must be a thorough understanding of the physiology and function of skeletal muscle. The cells 
used for skeletal muscle tissue engineering requires microenvironment similar to the natural 
skeletal muscle tissue, physically, chemically, and biologically similar. Once the cells are provided 
with a combination of optimal cues, the cells will form a skeletal muscle tissue with better 
morphology and function. 
 Current trends in skeletal muscle tissue engineering is more focused on combining 
different approaches. For instance, combination of a physical and chemical stimulation can 
potentiate myogenic differentiation. A substrate introduced with grooved pattern and a cell-
adhesive peptide, RGD, can promote adhesion, growth, and differentiation better than a substrate 
with only grooved pattern or RGD peptide.57 Some studies have shown combinatorial usage of the 
biological and physical approaches by transplanting transfected cells loaded on a decellularized 
matrix and physically training the transplanted tissue.29 Providing mechanical stimulation to the 
skeletal muscle co-cultured with vascular channel also improved myogenesis and muscle 
regeneration.58  
 Altogether, physical, chemical and biological cues must be considered when designing a 
culture system for engineering skeletal muscle. With appropriate signals provided to the myoblasts, 
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AT THE NEUROMUSCULAR JUNCTION 
Acknowledgments 
This work was supported by the National Science Foundation (CBET-140349 & STC-EBICS 
Grant CBET-0939511) and the National Institute of Biomedical Imaging and Bioengineering of 
the National Institutes of Health under Award Number T32EB019944. I would like to thank Dr. 
Seung Jung Yu for providing the material platform, Dr. Ziad Mahmassani for providing the 
primary cells, and Gelson J. Pagan-Diaz for his help in analyzing the functionality data. This 
chapter is adapted from Ko, E.; Yu, S. J.; Pagan-Diaz, G. J.; Mahmassani, Z.; Boppart, M. D.; Im, 
S. G.; Bashir, R.; Kong, H. Matrix Topography Regulates Synaptic Transmission at the 
Neuromuscular Junction. Advanced Science 2018, advs.201801521. Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission. Wiley-VCH hereby licenses back to 
the Contributor the following rights with respect to the final published version of the Contribution: 
 
3.1 Introduction 
 Skeletal muscle injuries characterized with strain and contusion often lead to significant 
reduction in the mass and strength of skeletal muscle. Without proper treatments, these 
pathological conditions may lead to discomfort, pain, disability, and ultimately death. In many 
cases, the muscular impairment accompanies regression and limited self-regeneration of 
neuromuscular junctions. The neuromuscular junction is a specialized synapse at the junction of 
the motor neuron and myofiber, a critical site that supports neural transmitter release and 
subsequent regulation of muscle contraction.1-2 Morbid or dysfunctional neuromuscular junction 
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causes a series of neuromuscular disorders and diseases.3-5 Thus, the formation and impairment of 
the neuromuscular junction have been extensively studied, largely through in vivo studies. 
Recently, engineering a muscle tissue innervated by neurons has gained attention because 
the system potentially allows physiological studies of both normal and impaired tissues at varied 
length scales. Moreover, the engineered neuromuscular junction could be useful for screening 
newly developed medicine related to muscular disorders and creating stimulatory devices.6-7 The 
neuromuscular junctions are commonly reproduced by co-culturing the skeletal myoblasts and 
neuronal cells.7-10 For example, a muscle strip co-cultured with stem cell-derived motor neurons 
exhibits a contraction profile by a natural neurotransmitter (e.g. glutamate) and an antagonist (e.g. 
curare).10 In addition, a microfluidic system was used to spatially organize myotubes and motor 
neurons and induce neural innervation into the myotubes.7 These studies largely focused on 
evaluating capability of stem cell-derived neural cells to innervate muscle tissue. Despite these 
impressive successes, the underlying basis for cross-talk between muscle and neurons at the 
neuron-muscle interface is still not sufficiently understood. 
Previous studies conducted in vivo suggest that communication between the muscle and 
motor neurons guide neural innervation.11-12 These studies reported that myogenic differentiation 
in the post-synaptic region can guide synaptogenesis.11 For instance, the muscle intrinsically 
activates muscle-specific kinase that mediates the expression of acetylcholine receptors, which act 
as a physical pattern at the post-synaptic region. The innervating neurons, on the other hand, 
secrete agrin proteins that phosphorylates the muscle-specific kinase and stabilize the clustered 
acetylcholine receptors in the muscle.13-14 The muscle and neurons communicate during these 
reciprocal events to form neuromuscular junctions. These results imply that a series of intercellular 
signaling events in the muscle can mediate the neural innervation.  
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In this study, we hypothesized that the maturity and alignment of myotubes engineered in 
vitro would affect the expression of acetylcholine receptors in myotubes and responsiveness of 
neuron-innervating muscle to the neurotransmitter and antagonist. First, we cultured primary or 
C2C12 skeletal myoblasts on the Matrigel-coated poly(urethane acrylate) (PUA) substrates with 
grooved patterns (Figure 3.1). The groove width was varied from 200 nm to 800 and 1,600 nm, 
which encompasses the geometry of collagen fibers in an extracellular matrix (ECM) and 
myofibrils of the muscle fiber.15-16 A flat PUA substrate was used as a control. Next, on the pre-
formed myotubes, we plated neural stem cells (NSCs) and differentiated them into motor neuron 
progenitor cells. We examined the differentiation lineage and angular alignment of NSCs via 
immunofluorescence imaging. Lastly, the neural innervation into myotubes were evaluated by 
immunofluorescently staining the myosin heavy chain (MHC), acetylcholine receptor, and 
presynaptic ends of the neurons. The physiological function of the neuromuscular junction was 
also assessed by measuring the contraction frequency upon exposure to an excitatory 
neurotransmitter (i.e., glutamate) and a neuromuscular antagonist (i.e., curare).9 
 
3.2 Results and Discussion 
3.2.1 Engineering Myotubes on the Grooved Substrates  
First, we prepared PUA substrates with controlled patterns of grooves ranging from 200 to 
1,600 nm. These substrates were fabricated by placing PUA resin and poly (ethylene terephthalate) 
(PET) film on the silicon molds as previously described (Figure 3.2A).17 The topographical feature 
of the pattern was confirmed by scanning electron microscopy images (Figure 3.2B). These 
grooved substrates were inspired by the structure of muscle.17 The cross-sectional diameter of a 
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myofibril is around 1 µm.18 In contrast, collagen fibers, the ECM protein surrounding the skeletal 
muscle, have cross-sectional diameters ranging between 200 and 400 nm.19 
 We investigated if the grooved substrates modulate the organization of cytoskeletal actin 
filaments and focal adhesion proteins of the primary and C2C12 myoblasts (Figure 3). According 
to the immunofluorescence images of F-actin, the F-actin filaments of primary myoblasts aligned 
anisotropically on the grooved substrates, while the orientation was random on a flat substrate 
(Figure 3.3A, B). Vinculin was elongated in parallel with the linear pattern of the grooves in the 
immunofluorescence images. The linear orientation and elongation in the morphology of the focal 
adhesion complex may contribute to enhanced myogenic differentiation and muscle function after 
myoblasts differentiate into myotubes.20-21 In addition, the primary myoblasts displayed slightly 
increased expression levels of vinculin, on the substrate with the groove width of 1,600 nm (Figure 
3.3C). 
 The angular orientations of the cells were quantified with the optical images of cells 
(Figure 3.4). According to the optical images, both primary and C2C12 myoblasts cultured on the 
grooved substrates aligned in parallel with the grooves. The cells cultured on the flat substrate 
were, however, randomly oriented. The angular orientation was plotted from 0º to 180º on a 
histogram using the Directionality plugin in Image J software. This process yielded the histograms 
in Figure 4 B and D. The y axis indicates the magnitude of Fourier component and the x axis shows 
the degree. A single high peak with a low dispersion value, and high goodness of fit in the grooved 
groups suggest that the cells recognize the grooved patterns and align to each other. The flat group 
showed high dispersion value with low goodness of fit indicating the random orientation of cells. 
 The role of substrate topography on myogenic differentiation level was evaluated by 
examining the alignment and maturity of the multinucleated myotubes. After 10 days of culture in 
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the myogenic differentiation medium, the myotubes were stained for F-actin, myosin heavy chain 
(MHC), and cell nuclei (Figure 3.5). All three substrates prompted myoblasts to form MHC-
positive myotubes characterized with multinucleation. (Figure 3.5A, B). As expected, the grooved 
substrates guided the myotubes to align anisotropically while myotubes formed on the flat 
substrate developed in random directions. We further confirmed the myogenic maturation by 
examining the sarcomeric striation (Figure 3.5 C, D and Figure 6). The myotubes formed with 
both primary and C2C12 myoblasts cultured on the grooved substrates promoted striation of the 
myotubes. The relative number of striated myotubes was higher when myoblasts were cultured on 
the grooved substrates compared to the flat substrate. 
 With the immunofluorescence images, we performed a morphometric analysis by 
measuring the width, length, area, and fusion index of MHC-positive myotubes. These 
morphometric parameters represent maturity of myotubes. There were significant differences in 
the size of myotubes between conditions. The myoblasts cultured on the substrate with the groove 
width of 1,600 nm developed MHC-positive myotubes with the largest width and length (Figure 
3.5E, F). The MHC-positive area of myotubes was also proportional to the width of the grooves. 
The dependency was more noticeable with primary myoblasts than C2C12 myoblasts (Figure 
3.5G). The fusion index was quantified by dividing the number of nuclei present in the 
multinucleated myotubes by the total number of nuclei present (Figure 3.5H). The fusion index of 
cells cultured on the grooved substrates was higher than that on the flat substrate, indicating that 
grooved substrates are advantageous to stimulating mature myotube formation.  
 We also examined the MHC-positive myotubes formed on the substrate with the groove 
width of 800 nm. These myotubes showed minimal differences in the myotube width and area, 
compared with those formed on the substrate with the groove width of 200 nm (Figure 3.3.7). 
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Therefore, we used substrates with the groove width of 200 and 1,600 nm for the following co-
culture study. 
 
3.2.2 Analysis of Neuronal Differentiation of NSCs on Engineered Myotubes 
 We studied if the maturity and alignment of myotubes formed on the flat and grooved 
substrates affect the differentiation lineage of NSCs and the orientation of the differentiated NSCs. 
We used NSCs because of their potential to differentiate into motor neurons. 10, 22-23 As the first 
step, we prepared a myotube layer, which covered the flat or grooved substrates entirely. Then, we 
plated the globular clusters of NSCs, denoted as neurospheres, on the myotubes layer.  This 
allows the NSCs to recognize the orientation of the myotubes instead of the topology of the 
substrates. Within 3 days, single cells migrated from the neurospheres and adhered on the 
myotubes. 10, 24  
 The cells migrated from the neurospheres differentiated into motor neuron progenitor cells 
spontaneously, as confirmed with motor neuron markers, including islet 1 and neurogenin 2 
(Figure 3.8A-D). Islet 1 is a transcription factor essential for differentiating into motor neurons 
and neurogenin 2 is a transcription factor that specifies motor neuron identity.25-28 The motor 
neuron progenitor cells positively stained by antibodies to islet 1 and neurogenin 2 stretched their 
axons in parallel to the myotubes, particularly those formed on the grooved substrate. The motor 
neuron progenitor cells oriented randomly on the myotubes formed on the flat substrate.  The 
differentiated NSCs were also stained with a neuronal marker, microtubule-associated protein 2 
(MAP2) and a glial marker, glial fibrillary acidic proteins (GFAP). These immunofluorescence 
images exhibited that the NSCs differentiated into neuronal cells more actively than glial cells 
when the myotube layer was present (Figure 3.9 A, B). The spontaneous neuronal differentiation 
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of NSCs was observed without the myotubes, as confirmed with positive staining for MAP2, 
neurofilament, islet 1 and neurogenin 2 (Figure 3.9C). However, in this condition, differentiated 
NSCs also expressed GFAP. 
 The immunofluorescence images of differentiated neurons were analyzed with ImageJ 
software to determine the angular orientation. Angular orientation was plotted as histograms, and 
the direction (population mean) and dispersion (standard deviation) were obtained (Figure 3.8 E, 
F). The neurons cultured on myotubes aligned by the grooved substrates showed two high peaks 
localized at single peak, with a small dispersion value confirming anisotropic alignment of neurons 
(Figure 3.8E, F). The goodness of fit values were above 0.8 indicating that the myoblasts 
anisotropically aligned better compared to the myoblasts cultured on the flat substrate. Neurons on 
the myotubes formed on the flat substrates showed a large dispersion value with a low goodness 
of fit. Thus, the cells were more randomly oriented.  
 The linear topographical features are known to regulate the differentiation level of NSCs 
and the spatial organization of the differentiated neurons.28-29 The axons of neurons tend to extend 
more on the linear topography where neurotrophic factors are immobilized.30 Apart from these 
prior studies, this study was conducted by culturing the neurospheres on the myotube layer, which 
shadowed the substrate pattern. Therefore, this anisotropic alignment of differentiated neurons 
with myotubes addresses that myotubes can guide the orientation of neurons during this sequential 
co-culture. Moreover, the anisotropically aligned ECM molecules produced by the myotubes, such 
as collagen, could have guided the orientation of the differentiated neurons. The axons stretching 
to relatively random directions on the flat substrate support this interpretation. 
 
3.2.3 Morphological Analysis of the Neuron-Muscle Interface  
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 We examined the mutual interaction between the myotubes and neurons by examining the 
acetylcholine receptor expression on the myotubes and the neural innervation. Again, myoblasts 
were cultured on the grooved substrates to form mature myotubes, and neurospheres were plated 
on the myotubes subsequently. The acetylcholine receptors, MHC, and neurofilaments of 
differentiated neurons were visualized via immunostaining. On the flat substrate, myotubes and 
neurons were extended in random directions, as shown with isotropic orientations of the MHCs 
and neurofilaments (Figures 7A, C). The myotubes on the grooved substrates aligned together with 
the differentiated neurons, as displayed with the same orientations of MHCs and neurofilaments. 
Moreover, myotubes formed on the substrates with the groove width of 1,600 nm presented larger 
number of acetylcholine receptors than those formed on the flat substrate, particularly with 
myotubes formed with primary myoblasts (Images in the first rows of Figures 7A and 7C). Then, 
we visualized synaptophysin (pre-synaptic marker) and acetylcholine receptor (post-synaptic 
marker) to locate the sites where neurons innervate (Figures 7B and 7D). All conditions showed 
synaptophysin-positive nerve ends on myotubes. To confirm the nerve ends, differentiated NSCs 
were additionally stained with MAP2 for the primary myoblast condition. 
Based on the immunofluorescence images, we quantified the relative acetylcholine receptor 
positive area per myotube in the immunofluorescence image and the area of co-localization of the 
acetylcholine receptors, MHC, and neurofilaments per myotube. According to the quantitative 
analysis with immunofluorescence images, myotubes developed on the grooved substrates 
expressed a higher level of acetylcholine receptors than those on the flat substrate (Figure 3.10E). 
Increasing the groove width from 200 to 1,600 nm led to a 1.7-fold increase in the acetylcholine 
receptors expression level in primary myoblast-derived myotubes. With C2C12 myoblast-derived 
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myotubes, the substrate with the groove width of 1,600 nm led to the fivefold higher acetylcholine 
receptor expression than the flat substrate (Figure 3.10G).  
 Likewise, primary myoblast-derived myotubes on the substrate with the groove width of 
1,600 nm showed a nearly two-fold higher percentage of area co-localized by acetylcholine 
receptors and neurofilaments than those formed on the flat substrate (Figure 3.10F). This result 
implies that an increased number of myotubes were innervated by motor neuron progenitor cells 
on the grooved substrate.  The myotubes prepared with C2C12 myoblasts showed a similar trend 
(Figure 3.10H). The fluorescence channels were separated to show a clearer expression of each 
marker (Figure 3.11).  
 
3.2.4 Functional Analysis of the Neuron-Muscle Interface  
 Finally, we evaluated functionality of the motor neuron progenitor cell-innervated 
myotubes by recording their response upon exposure to the excitatory neurotransmitter, glutamate, 
and the neuromuscular junction-specific antagonist, curare (Figure 3.12A). Before exposure to 
glutamate or curare, myotubes showed slightly noticeable spontaneous contraction, regardless of 
the substrate topography (Figures 8B-E). The myotubes engineered with both primary and C2C12 
myoblasts on the substrate with groove width of 1,600 nm responded to glutamate and curare more 
sensitively. The degree of response was specific to cell types. Upon exposure to glutamate, motor 
neuron progenitor cell-innervated myotubes on the substrate with groove width of 1,600 nm 
showed higher contraction frequency and number than those formed on the substrate with groove 
width of 200 nm (Figure 3.12B, Table 1). The myotubes on the flat substrate exhibited an almost 
imperceptible increase in the contraction frequency.  
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 When the samples were exposed to curare, motor neuron progenitor cell-innervated 
myotubes on the substrate with groove width of 1,600 nm instantaneously switched off. The motor 
neuron progenitor cell-innervated myotubes on the other two substrates showed a lag time ranging 
from 2 to 5 seconds before the contraction stopped completely (Figure 3.12C). 
 The difference in muscle contraction between conditions became smaller with myotubes 
formed with C2C12 myoblasts. Upon exposure to glutamate, there was either proportional 
increases in the contraction frequency or number with the increase in groove width (Figure 3.12D, 
Table 1). The muscle contraction was shut down within 5 seconds for all samples when the samples 
were exposed to curare (Figure 3.12E, Table 1).  
The myotubes formed without NSCs did not show a notable response to either glutamate 
or curare (Figure 3.13). In fact, contraction was either slightly noticeable or not recognizable in 
the culture. Addition of glutamate to the primary and C2C12 myoblasts did not show significant 
change in the contraction (Figure 3.13 A, C). Similarly, the myotubes continuously contracted 
after applying curare to the samples (Figure 3.13 B, D). Because glutamate promotes motor 
neurons to secrete more acetylcholine molecules from the motor neurons to the skeletal myotubes 
and enhance contraction, the myotubes without the motor neuron progenitor cells did not respond 
to glutamate treatment. Curare blocks the acetylcholine receptors in the skeletal myotubes. The 
blockage of these sites did not have any influence the spontaneous contraction in absence of the 
motor neuron progenitor cells.  
 These results address that maturity and orientation of myotubes play important roles in 
reproducing the neuron-innervated muscle with an increased sensitivity to glutamate and curare. 
We suggest that the grooves on the substrates present increased contact area for the myotubes and 
align the cells anisotropically. In fact, grooves with 200 nm-spacing are not wide enough for the 
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cellular membrane to penetrate and form contacts between a substrate and cells, as confirmed with 
the electron microscopic images (Figure 3.14).31 On the other hand, myotubes cultured on the 
substrate with the groove width of 1,600 nm protrude their membrane into the grooves. 
Accordingly, myotubes align with the grooved pattern better than those on the 200 nm grooved 
substrate. We propose that this enhanced contact with the substrate promotes the anisotropic 
alignment of myotubes along the grooved pattern.  
 From the analysis of neuron-muscle interface, we propose that myotubes regulate the 
lineage of the NSCs and the spatial arrangement of the differentiated motor neuron progenitor cells. 
The maturity of myotubes influences the acetylcholine receptor expression level, which directly 
promotes the neuronal differentiation.32 The presence of muscle-derived neurotrophic factors 
could also contribute to the development and differentiation of NSCs to motor neuron progenitor 
cells, as maintenance and function of motor neurons depend on secreted factors from the skeletal 
muscle.33-34 Moreover, the aligned myotubes express more acetylcholine receptors, thus, increase 
the number of neuron-innervated myotubes as characterized with the immunofluorescence staining 
of neuron-muscle interface and the response to glutamate and curare. These results confirm that 
acetylcholine receptors on the myotubes guide and stimulate neural innervation, as previously 
suggested with the in vivo gene knock-out studies.35-38 Likely, the agrin molecules secreted by 
innervating neurons stimulate the aggregation of acetylcholine receptors, which would be 
systematically examined in future studies.13-14   
 This study provides crucial insights into engineering muscles, morphologically and 
functionally similar to the natural muscle. To the best of our knowledge, we have demonstrated 
that the maturity of muscle promotes the neural innervation by mediating the reciprocity between 
myotubes and neurons for the first time. As a consequence, myotubes display rapid response time, 
 
 31 
and increased contraction number in response to a neural simulator and inhibitor. We proposed 
that this finding make important scientific impacts in understanding the homeostasis of the normal 
muscle and the regeneration of the functional muscle. In the long term, this system may work as a 
vital component of controlling the stimulus responsive behavior of a “living” biological machinery, 
emerged as a new generation of an autonomous robotic system.39-41 
 
3.3 Conclusion 
 In conclusion, this study uncovered an important role of the muscular orientation and 
maturity in neural innervation and the physiological function of neuromuscular junctions. The 
nanogrooved substrates with proper groove width facilitated the formation of mature and aligned 
myotubes compared to the flat substrate. The NSCs subsequently plated on the mature and aligned 
myotubes differentiated into motor neuron progenitor cells and aligned in the same direction of 
the pre-formed myotubes. The mature and aligned myotubes formed on the substrate with groove 
width of 1,600 nm raised the acetylcholine receptor expression level and the percentage of area 
where motor neuron progenitor cells and acetylcholine receptors are co-localized, compared to 
myotubes formed on the flat substrate. In consequence, the response of neuron-innervated muscle 
contraction to glutamate and curare was more evident when myotubes were more aligned and 
mature. Altogether, results of this study illuminate the reciprocal activity of myotubes and neurons 
toward the assembly of the physiologically functional muscle. Therefore, these findings would be 
useful to improving the quality of engineered tissue used for drug screening, muscular disorder 
treatment, and biological machinery assembly. 
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3.4 Materials and Methods 
3.4.1.Preparation of Nano-Grooved Substrates 
The nanogrooved substrates were fabricated with PUA (MINS-311RM, Minuta Tech, Gyeonggi, 
Korea) by using the capillary force lithography techniques reported previously.17 Two drops of 
PUA resin were placed at the center of a nanogrooved Si master and subsequently covered with 
PET film (Skyrol ®, SKC Co., Ltd., Seoul, Korea). The PUA resin was exposed to ultraviolet light 
at 20 mW/cm2 for 10 seconds in the UV curing system (Minuta Tech, Gyeonggi, Korea) (~365 
nm). Then, the PET film with the patterned PUA resin was detached from the Si mater and 
stabilized for 24 hours. The substrates were soaked in isopropyl alcohol for 30 minutes and distilled 
water for an additional 30 minutes. The flat PUA substrate was prepared on the smooth Si surface 
by following the same curing and cleaning procedure. 
 
3.4.2 Primary Myoblast Isolation and Culture  
Mice were sacrificed using CO2 inhalation followed by cervical dislocation.  Sacrificed mice were 
placed on ethanol and transferred to a sterile culture hood.  Hind limb muscles were dissected and 
minced in a petri dish 1% (v/v) penicillin/streptomycin antibiotic in sterile phosphate buffer saline 
(PBS).  Enzyme solution containing 10% (w/v) Pronase, 3.5% (w/v) Collagenase, and 2.5mm 
CaCl2 was introduced to the slurry mix and allowed to incubate for 1 hour at 37 °C with trituration 
every 10 minutes.  The mixture was then passed through a 70μM filter where a volume of 
inhibition medium (20% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin in 
Hanks’ balanced salt solution) equal to the volume of enzyme solution used was added.  The 
solution was, again, passed through a 40μM filter.  The conical tubes containing the muscle slurry 
were spun at 350g for 5 minutes, and the pellet was re-suspended in the growth medium.  Cells 
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were pre-plated on plastic petri dishes for 3 hours, after which the unattached cells were plated on 
Matrigel coated (1% (v/v) Matrigel in sterile PBS) Petri dishes.  Cells were not allowed past 75% 
confluence during the passage. 
 
3.4.3 Culture of Primary and C2C12 Myoblasts for Myogenic Differentiation 
The fabricated PUA substrates were sterilized by using 70 % ethanol and washed with sterile PBS 
three times before use. The surfaces were coated with Matrigel (Corning, New York, NY, USA) 
to allow cell adhesion. For the coating process, 1% (v/v) Matrigel in PBS was placed on the PUA 
substrates and incubated for 1 hour. The excess solution was removed by washing the substrates 
with PBS 2 times. The primary myoblasts or C2C12 myoblasts (American Type Culture Collection, 
Rockville, MD, USA) were plated on the PUA substrate at a density of 2 × 104 cells/cm2. The PUA 
substrates plated with primary myoblasts were incubated in growth medium consisting of 
Dulbecco’s modified Eagle medium (DMEM) /F12 50:50 (Corning), r-fibroblast growth factor 
(FGF), 1% penicillin-streptomycin (PS, Gibco, Gaithersburg, MD, USA), 20% FBS (Gibco). The 
cells were incubated in humidified air containing 5% CO2 at 37 °C. Separately, the PUA substrate 
on which C2C12 myoblasts cultured were incubated in DMEM (Gibco) supplemented with 10% 
FBS (Gibco) and 1% PS. Myogenic differentiation of both primary cells and C2C12 cells was 
activated by replacing the growth medium with a differentiation medium (DMEM supplemented 
with 2% horse serum and 1% PS) after 3 days of culture in the growth medium. The cells were 
incubated in the differentiation medium for additional 7 days. 
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3.4.4 Culture of NSCs for Neuronal Differentiation 
NSCs derived from the mouse brain cortex were purchased from R&D Systems (Minneapolis, MN, 
USA) and expanded in a neurosphere form by following the manufacturer’s protocol. In brief, the 
cells were plated at a density of 5 × 104 cells/ml and cultured in DMEM/F12 medium supplemented 
with the N-2 supplement (R&D Systems), the epidermal growth factor (EGF) (R&D Systems), 
and the basic recombinant human fibroblast growth factor (bFGF) (R&D Systems). Fresh EGF 
and bFGF were added every day during expansion. After culturing the neurospheres in growth 
medium for 5 days, the medium was replaced with the neural differentiation medium (DMEM/F12 
medium supplemented with N-2 supplement (R&D Systems)). The neurospheres were cultured for 
3 days to induce neuronal differentiation before initiating the co-culture with the myotubes.  
 
3.4.5 Co-Culture of the Differentiated Myoblasts and NSC Neurospheres 
Primary and C2C12 myoblasts were seeded on the PUA substrates coated with Matrigel and 
differentiated as above. Then, NSC neurospheres cultured in the neural differentiation medium for 
3 days were collected and placed on the engineered muscle layer. The two cell populations were 
incubated in the NSC differentiation medium overnight for stabilization of NSCs. On the next day, 
the medium was replaced with NSC differentiation medium containing 2% horse serum. The horse 
serum was included in the co-culture media to maintain the differentiated myotubes.42 The 
myoblasts and NSCs were maintained in the co-culture medium for another 7 days. 
 
3.4.6 Immunofluorescence Staining of F-Actin and Vinculin 
Myoblasts cultured on the flat and grooved substrates were stained for F-actin, vinculin, and 4'-6-
diamidino-2-phenylindole (DAPI) using the Actin Cytoskeleton and Focal Adhesion Staining Kits 
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(FAK100) (Millipore, Bedford, MA, USA). In brief, after 3 days of culture, cells on the PUA 
substrates were fixed with 4% (w/v) paraformaldehyde (Sigma, St. Louis, MO, USA) for 15 min 
and permeablized with 0.1% (v/v) Triton X-100 (Sigma) for 5 min. After incubating the cells in 
2% goat serum for blocking unspecific bindings, the cells were incubated with primary vinculin 
antibody for one hour at room temperature. Then, vinculin was immunofluorescently labeled with 
secondary antibodies (Alexa Fluor-594 donkey anti-mouse IgG; Invitrogen, Carlsbad, CA, USA). 
For double immunofluorescence staining, fluorescein (FITC)-conjugated Phalloidin included in 
the kit was applied simultaneously. After incubation for 1 hour, the nuclei of the cells were labeled 
with DAPI (Sigma). The fluorescence signals were collected with a laser scanning confocal 
microscope (LSM 700, Carl Zeiss, Jena, Germany). 
 
3.4.7 Analysis of Cellular Orientation 
The morphology images of the myoblasts were taken with an inverted microscope 
(Leica DMI 4000B, Leica Microsystems, Wetzlar, Germany) after the myoblasts were cultured in 
growth medium for 3 days and differentiation medium for 7 days. The directionality of the adhered 
cells was analyzed by Directionality plugin for ImageJ software. First, the morphology images 
were converted to 8-bit grayscale images, and these images were processed with Directionality 
plugin available on the Analyze tab. This plugin derives a histogram that counts the amount of 
myotubes in each degree from 0º to 180º. A Gaussian fit is calculated from the highest peak in the 
histogram. Direction of the myotubes in degree (mean) and the dispersion of the myotubes in 
degree (standard deviation) were derived by the plug in.43 Similarly, the alignment of NSCs 
cultured on the myotubes was analyzed by following the same procedure. Immunofluorescence 
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images of the neurons positively stained for MAP2 were used for this analysis. The goodness of 
fit R2 value was averaged to confirm orientation of the myotubes. 
 
3.4.8 Immunofluorescence Staining of Myotubes and Morphometric Analysis 
After culturing the myoblasts for 7 days in the myogenic differentiation medium, we 
immunofluorescently stained the cells. Cells were fixed with 4% (w/v) paraformaldehyde (Sigma) 
for 15 min, permeablized with 0.1% (v/v) Triton X-100 (Sigma) for 5 min and incubated in 
blocking solution for 45 min. After blocking, the cells were incubated with MF-20 anti-MHC 
(1:400) (iT FX, Developmental Studies Hybridoma Bank, The University of Iowa Department of 
Biology) at 4 °C overnight. Another set of samples were incubated with anti-sarcomeric a-actinin 
antibody (Abcam Cambridge, U.K.). On the next day, MHC was labeled with fluorescence-tagged 
secondary antibody (Alexa Fluor-594 goat anti-mouse IgG (1:500) (Invitrogen)) and sarcomeric 
a-actinin was labeled with Alexa Fluor-568 donkey anti-rabbit IgG (1:500; Invitrogen). 
Additionally, phalloidin-Alexa Fluor 488 (1:200; Invitrogen) and DAPI (Sigma) were used to stain 
F-actin and nuclei of the cells, respectively. The length and width of the myotubes were quantified 
by measuring the length and width of the MHC-stained myotubes present in the 
immunofluorescence image. The MHC-positive area was calculated by quantifying the number of 
pixels. The fusion index was quantified by calculating the ratio of the number of nuclei in the 
differentiated myoblasts. The samples were imaged with the laser scanning confocal microscope 
(LSM 700, Carl Zeiss).  
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3.4.9 Immunocytochemical Analysis of Differentiated Neurons  
The immunofluorescence staining of NSCs cultured on the myotubes was fixed, permeabilized, 
and blocked. Then, the samples were incubated with the motor neuron marker, rabbit monoclonal 
anti-islet 1 (1:100; Abcam) and rabbit polyclonal anti-neurogenin 2 (1:100; Abcam). Islet 1 and 
neurogenin 2 were labeled with Alexa Fluor-488 donkey anti-rabbit IgG (1:500; Invitrogen). Then, 
another sample set was incubated with mouse monoclonal anti-glial fibrillary acidic protein 
(GFAP) (1:200; Millipore), and rabbit polyclonal anti-microtubule- associated protein (MAP2) 
(1:200; Abcam) at 4°C. The GFAP and MAP2 were labeled with Alexa Fluor-488 donkey anti-
rabbit IgG (1:500; Invitrogen) and Alexa Fluor-594 donkey anti-mouse IgG (1:500; Invitrogen), 
respectively. The nuclei of cells were separately stained with DAPI. The samples were imaged by 
the confocal microscope (LSM 700, Carl Zeiss).  
 
3.4.10 Immunocytochemical Analysis of the Neuromuscular Junctions 
The neuromuscular junctions were identified with a site where acetylcholine receptors on the 
MHC-positive myotubes and the synaptic ends of the neurofilaments were co-localized. The cells 
were fixed, permeabilized, and blocked. After blocking, one set of samples was incubated with 
primary antibodies, MF-20 anti-myosin heavy chain (MHC; 1:400) (iT FX) and neurofilament-H 
(neurofilament 200) (1:50; Sigma) at 4 °C. Another set of samples was treated with chicken 
polyclonal anti-MAP2 (1:1000; Abcam), and rabbit monoclonal anti-synaptophysin (1:250; 
Thermo Fisher Scientific, Rockford, IL, USA) to label the myotubes and pre-synaptic ends of the 
motor neuron progenitor cells. Lastly, cells treated with MF-20 and neurofilament-H were 
incubated with Alexa Fluor-488 donkey anti-rabbit IgG (1:500; Invitrogen) and Alexa Fluor-594 
goat anti-mouse IgG (1:500) (Invitrogen). The samples treated with anti-MAP2 antibody and 
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synaptophysin were treated with Alexa Fluor-488 goat anti-chicken IgG (1:500; Invitrogen) and 
Alexa Fluor-568 donkey anti-rabbit IgG (1:500) (Invitrogen). The cells were also incubated with 
the α-Bungarotoxin-Alexa Fluor-647 conjugate (1:1000; Invitrogen) to label acetylcholine 
receptors on the myotubes. Next, the nuclei were stained using DAPI (Sigma). The final samples 
were observed under a multiphoton confocal microscope (LSM 710, Carl Zeiss). 
 
3.4.11 Functionality Analysis of the Engineered Neuromuscular Junctions 
The engineered neuromuscular junctions on the substrates were treated with a neurotransmitter, 
glutamate (400 M, Sigma), or an antagonist, (+)-Tubocurarine chloride hydrochloride 
pentahydrate (curare) (50 M, Abcam), to stimulate or stop the muscle contraction, respectively. 
Videos were taken using Zeiss Axiocam ERc 5s (Carl Zeiss) attached on an inverted microscope 
at 30 fps and later processed using FIJI and MatLAB. The region of interest was determined by 
selecting 6 active regions in the beginning of data acquisition distributed evenly across the entire 
field of view. The region of interests were loaded unto MATLAB and tracked displacement of 
myotube periphery. Modulus of displacement was calculated between each phrase using standard 
distance formula. Contractions were assigned by selecting positive values after calculating the 
discreet derivatives of the displacement arrays. Contractions were summed for each frame and 
plotted against time. The analysis for the control group was performed same as above, but the 
myotubes were treated without the neural stem cells. 
 
3.4.12 Statistical Analysis 
All statistical analyses performed in this study were conducted using unpaired Student's t-test with 
Graph Pad Prism 6.0 (Graph Pad Software Inc., San Diego, CA, USA). Differences were 
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considered significant at a p-value of less than 0.05. p-value smaller than 0.05, were considered 
statistically significant. 
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3.5 Figures and Table 
 
Figure 3.1 Schematic description of engineering the neuromuscular junction through the 
sequential co-culture of skeletal myoblasts and NSCs on the Matrigel-coated PUA substrates. The 




Figure 3.2 Fabrication procedure and analysis of the grooved PUA substrates. (A) Schematic 
description of the fabrication procedure of the grooved substrates. (B) Scanning electron 
microscope images of the flat PUA substrate, PUA substrate with 200 nm-groove width (w), and 
PUA substrate with 1,600 nm-groove width (w). Images in the first and second rows represent the 




Figure 3.3 Immunofluorescence staining of F-actin (green), vinculin (red), and nucleus (blue) of 
primary myoblasts (A) and C2C12 myoblasts (B). The images on the second row of A are 
magnified views of the area boxed in images. Images were captured 3 days after culture. (C) The 
vinculin expression level quantified with the immunofluorescence images. Each condition was 
normalized to the vinculin expression value of primary myoblasts adhered to the flat substrate. * 
represent the statistical significance of the difference of the values between conditions noted in 




Figure 3.4 Angular orientation analysis of the skeletal myoblasts. The primary myoblasts (A, B) 
and C2C12 myoblasts (C, D) were cultured for 7 days on the flat substrate, a grooved pattern with 
200 nm-width, and grooved pattern with 1,600 nm-width. (A, C) Morphology images of the 
primary myoblasts and C2C12 myoblasts, respectively. (B, D) Representative histograms of the 
orientation of primary myoblasts and C2C12 myoblasts. The average value of goodness of fit (R2) 
is indicated as µ, and the standard deviation is indicated as σ (n=4).  
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Figure 3.5 Analysis of the myogenic differentiation of skeletal myoblasts. (A, B) 
Immunofluorescence images of the MHC (red), F-actin (green), and nucleus (blue) in the 
differentiated primary myoblasts (A) and C2C12 myoblasts (B) taken after 10 days of culture in 
myogenic differentiation medium. (C, D) Immunofluorescence images of the sarcomeric a-actinin 
(red), F-actin (green), and nucleus (blue) in the differentiated primary myoblasts (C) and C2C12 
myoblasts (D) taken after 10 days of culture in myogenic differentiation medium. (E-H) 
Morphometric analysis of the differentiated skeletal myoblasts based on the immunofluorescence 
images. The myotube width (E), myotube lengths (F), MHC-positive area (G), and fusion index 
(H) were quantitatively examined. In each plot, * and ** represent the statistical significance of 
the difference of the values between conditions noted in brackets (n=4, *p < 0.01, **p < 0.05).
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Figure 3.6 Immunofluorescence staining of sarcomeric a-actinin (red), F-actin (green), and 
nucleus (blue) of primary myoblasts and C2C12 myoblasts. Images were captured 10 days after 
culture. The graph represents the relative number of a-actinin positive myotubes per image. * and 
** represent the statistical significance of the difference of the values between conditions noted in 




Figure 3.7 Analysis of the myogenic differentiation of primary skeletal myoblasts cultured on 
substrates with different groove widths. (A) Immunofluorescence images of the MHC (red), F-
actin (green), and nucleus (blue) of myoblasts. Images were taken after 10 days of culture in 
differentiation medium. (B-E) Morphometric analysis of the differentiated skeletal myoblasts 
based on the immunofluorescence images. The myotube width (B), myotube lengths (C), MHC-
positive area (D) were examined quantitatively. In each plot, * and ** represent the statistical 
significance of the difference of the values between conditions noted in brackets (n=4, *p < 0.01, 
**p < 0.05). 
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Figure 3.8 Analysis of the differentiation and alignment of NSCs cultured on the myotubes. 
Immunofluorescence images of the differentiated NSCs on the myotubes formed with primary 
myoblasts (A, B) and C2C12 myoblasts (C, D). NSCs were stained positively for islet-1 (Isl-1, 
green in A, C), neurogenin-2 (NGN, green in B, D), and nucleus (blue) after 5 days of culture in 
the neural differentiation medium. Representative histogram showing the angular orientation of 
the differentiated NSCs on myotubes formed with primary myoblasts (E) and C2C12 myoblasts 
(F). The average value of goodness of fit (R2) is indicated as µ, and the standard deviation is 
indicated as σ (n=4).  
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Figure 3.9 Differentiated NSCs on the myotubes formed with primary myoblasts (A), C2C12 
myoblasts (B), and without myoblasts (C). In (A) and (B), the cells were labeled with MAP2 
(green), GFAP (red), and nucleus (blue). In (C), the cells were labeled with MAP2 (green), 
neurofilament (green), islet-1 (Isl-1, green), GFAP (red), and nucleus (blue) after 5 days of culture 




Figure 3.10 Immunocytochemistry of the neuron-innervated myotubes. Images were captured 
after the co-culture of primary myoblasts and C2C12 myoblasts with NSCs for 7 days. (A, C) 
Myotubes and neurons stained for MHC (red), neurofilament (NF, green), acetylcholine receptors 
(AchR, orange), and nucleus (blue). (B, D) Myotubes and neurons stained for synaptophysin (SNP, 
green), acetylcholine receptors (AchR, orange), and nucleus (blue). The motor neuron progenitor 
cells were additionally labeled with MAP2 (red) (B). (E, G) Quantified acetylcholine receptor 
expression levels (n=4, *p < 0.01, **p < 0.05). The relative acetylcholine receptor expression level 
was calculated by counting the number of pixels stained positively for acetylcholine receptors in 
each image and normalizing it to the number obtained with the flat substrate condition. (F, H) 
Average percentage of area where neurofilaments and acetylcholine receptors are co-localized in 
the myotubes (n=4, *p < 0.01, **p < 0.05). Images of (A), (B) and graphs of (C), (D) are the results 
for primary myoblasts-derived myotubes. Images of (C), (D) and graphs of (G), (H) are the results 
for C2C12 myoblasts-derived myotubes. 
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Figure 3.11   Immunocytochemistry of the neuron-innervated myotubes. Images were captured 
after the co-culture of primary myoblasts and C2C12 myoblasts with NSCs for 7 days. These 
images are the same images from Figure 10A-C showing separated channel images. 
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Figure 3.12 Functionality analysis of the neuron-innervated myotubes. (A) Schematic description 
of the increased contraction of neuron-innervated muscle by glutamate and the inhibited 
contraction by curare. (B) Triggered contraction of the primary myoblast-derived myotubes with 
the addition of glutamate. (C) Inhibited contraction of the primary myoblast-derived myotubes 
upon exposure to curare. (D) Triggered contraction of the C2C12 myoblast-derived myotubes with 
the addition of glutamate. (E) Inhibited contraction of the C2C12 myoblast-derived myotubes upon 
exposure to curare. In (B) and (D), arrows indicate the time point when glutamate was added. In 
(C) and (E), arrows indicate the time point when curare was added.  
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Figure 3.13 Functionality analysis of myotubes without motor neuron progenitor cell innervation. 
(A) Contraction change of the primary myoblast-derived myotubes with the addition of glutamate. 
(B) Contraction change of the primary myoblast-derived myotubes upon exposure to curare. (D) 
Contraction change of the C2C12 myoblast-derived myotubes with the addition of glutamate. (E) 
Contraction change of the C2C12 myoblast-derived myotubes upon exposure to curare (n=6).  
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Figure 3.14 Scanning electron microscope images of the primary myoblasts-derived myotubes on 
flat and grooved substrates. Arrows indicate the sites where the cell membrane was protruded. 
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Table 3.1. Description of the movies which correspond to Figure 3.12 B-E. 
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CHAPTER 4: STRATEGY TO REGULATE GAP JUNCTION PROTEIN EXPRESSION 
FOR MATURE MUSCLE DEVELOPMENT AND IMPROVED PUMP-BOT FUNCTION 
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4.1 Introduction 
Skeletal muscle tissue comprises 40% of the body mass and is responsible for locomotion 
and actuation.1 Damaged tissue or loss in muscle function cause the patients to experience pain, 
disability, and sometimes, death.2, 3 Due to its significant role in the in vivo system, extensive in 
vitro studies to regenerate the skeletal muscle have been performed. These studies include creating 
drug screening devices,3, 4 developing methodologies to recapitulate the natural muscle tissue5, 6 
and engineering 3D skeletal muscle tissue.7-9 Engineering muscle tissue in 3D has emerged a useful 
technique due to its potential applications. For example, a 3D engineered muscle can actuate bio-
inspired devices or transplanted to an in vivo model.9-11 To reconstruct the tissue in vitro, the 
engineered muscle must recapitulate the morphological property of the natural tissue and produce 
enough force. Particularly, force production is a significant factor since it directly relates to the 
functionality of skeletal muscle. Up to this point, most studies have relied on adding growth factors 
that promote myotube maturity or performing exercise with the engineered tissue to increase force 
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production. In addition to these elements, biological changes happening in the myoblasts during 
differentiation also relates to muscle maturity. 
Gap junction proteins connect neighboring cells together allowing exchange of ions and 
small molecule.12, 13 During the communication between the adjacent cells, electrical signals as 
well as interchanging metabolic molecules occur.14-16 Due to its significant roles in ion exchange 
and electrical signal transmission, the gap junction proteins, such as connexin 43, are abundant in 
cardiomyocytes, and skeletal myoblasts.17, 18 Connexin 43, which propagates action potential 
signals, are highly expressed in cardiac cells. As the electrical signals are transmitted continuously 
through these channels, the cardiomyocytes show synchronized contraction. In skeletal myoblasts, 
however, the connexin 43 proteins are prevalent only during early developmental stage and 
disappear once the myoblasts fuse together to form myotubes. This is because the muscle fibers 
are independently innervated by motor neurons to contract.17, 19 
The role of connexin 43 in skeletal muscle is not clearly revealed. The major function of 
connexin 43, so far, is known as facilitating the myotube formation during myogenic 
differentiation.20-22 Although the exact underlying mechanism is still not well known, reports have 
shown that myoblasts modified to overexpress connexin 43 forms myotube faster and promote 
myogenic markers to be expressed in higher extent after differentiation. It also has been reported 
that overexpression of connexin 43 in rhabdomyosarcoma cells promote gap junctional 
intercellular communication.23 The communication between the neighboring cells promoted fusion 
and myogenesis. Furthermore, the connexin 43 may also contribute to muscle generation since 
suppression of connexin 43 in osteoblasts in mice damaged skeletal muscle development and 
resulted in reduce in muscle weight.24   
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Taken together, we hypothesize that extending the expression time of connexin 43 could 
increase maturity and physiological functionality of engineered skeletal muscle. In particular, 
delayed downregulation of connexin 43 in myoblasts would contribute to active communication 
of the differentiating myoblasts during fusion. We cultured C2C12 skeletal myoblasts with ultra-
thin, reduced graphene oxide (rGO) flakes which act as glue to increase adhesion of the 
neighboring cells. (Figure 1). The connexin 43 expression and the maturity of differentiated 
myotubes were evaluated via immunofluorescence staining and quantitative real time polymerase 
chain reaction (qRT-PCR) at different time points. Gene sequencing was performed to explore the 
genetic change occurring at different stages of differentiation. Lastly, we evaluated the 
contractility of the engineered muscle by operating a biological machine we recently created to 
control fluid transport in a similar mechanism to an insect’s open heart.25 
 
4.2 Results and Discussion 
4.2.1 Characterization of rGO and Attachment to the C2C12 Myoblasts 
Transmission electron microscopy image of the rGO showed micron sized flakes (Figure 
4.3 A). The size of the rGO was, in average, 5.37 µm in length and 4.01µm in width. The Raman 
spectrum of the rGO showed two distinct peaks, known as G band and D band (Figure 4.3 B). As 
explained above, C2C12 myoblasts used for the experiments were collected on the second day 
after removing the unattached rGO by centrifugation (Figure 1).  
We performed a cytotoxicity test to measure the cytotoxicity of rGO at different 
concentrations by performing a Tryphan blue assay (Figure 4.5). The relative viability of rGO was 
measured by comparing the cell number at day 1, 3, 7 and 10. Here, we used 0 µg/ml, 3 µg/ml, 5 
µg/ml, and 10 µg/ml rGO dispersed in growth medium. The viability of the C2C12 myoblasts 
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treated with 3 µg/ml and 5 µg/ml rGO dropped compared to the control group but remained above 
70%. The myoblasts treated with 10 µg/ml rGO showed dramatic decrease in viability which 
dropped to 70% on day 1 and remained between 50 to 55 % on the following days.  
Based on the cytotoxicity result, we selected 5 µg/ml concentration to conduct further 
experiments. We quantified the rGO attached on the myoblasts after removing the unbound rGO 
and plating the cells on a cell culture dish. As the size of the rGO was in micron scale, the material 
was visible under an optical microscope (Figure 4.4 A). The total area that rGO occupying in the 
image was measured to calculate the attachment efficiency (Figure 4.4 B). The total area of rGO 
in the image was 2012.62 µm2 in average, which corresponds to 0.83% of the confluent myoblasts. 
 Treating cells with nanomaterials, such as carbon nanotubes, silver nanowires, as well as 
graphene, are still controversial because materials under 1 µm size may possibly be internalized 
by cells.26, 27 Furthermore, the effects of those materials in the cells are still not well reported. We 
could avoid the internalization of rGO by using micro scale rGO particle. As shown in our figure 
(Figure 2D), the particles adhered on the cellular membrane and were visible under a light 
microscope. Moreover, reduction of cell viability by more than 30% is considered cytotoxic 
according to the International Organization for Standardization (10993-5). To maximize the effect 
of rGO while avoiding the cytotoxic effect of rGO, we fixed the concentration of rGO to 5µg/ml 
for our experiments. 
 
4.2.2 Analysis of Connexin 43 Expression in C2C12 Myoblasts 
Connexin 43 expression in C2C12 myoblasts was analyzed by performing 
immunofluorescence imaging on day 3 (before differentiation), day 7 (early differentiation), and 
day 14 (terminal differentiation) (Figure 4.6 A). We compared connexin 43 expression in the rGO-
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treated C2C12 myoblasts with control C2C12 myoblasts. Connexin 43 (green color) was visible 
in both groups before differentiation. However, the expression of connexin 43 became lower once 
we induced differentiation by culturing the cells in differentiation medium. In contrast, rGO-
treated C2C12 cells expressed connexin 43 during early differentiation stage. The expression was 
down-regulated at terminal differentiation stage. This result was confirmed by quantifying the 
relative mRNA expression level with qRT-PCR (Figure 4.6 B). Relative connexin 43 expression 
level was measured on day 3, day 7 and day 14. The connexin 43 was 1.2-fold higher on day 3, 
1.4-fold higher on day 7, and 1.2-fold higher on day 14. We observed both upregulated connexin 
43 mRNA expression and delayed downregulation of connexin 43 mRNA expression with rGO-
treated C2C12 myoblasts.  
Connexin 43 expression is upregulated in mesenchymal stem cells (MSC) and 
cardiomyocytes upon treating the cells with rGO.26, 28 The authors stated that this phenomenon is 
due to the conductivity of rGO. In addition, rGO has adhesive characteristics to the surrounding 
proteins and molecules.29, 30 Therefore, we suggest the conductivity could have contributed to 
overexpression of connexin 43 on the cellular membrane. Moreover, the adhesive property of rGO 
would hold the connexin 43 proteins to remain on the cellular membrane longer.  
 
4.2.3 Analysis of Myogenic Differentiation of rGO-Treated C2C12 Myoblasts 
The effect of rGO on myogenic differentiation was analyzed by performing 
immunofluorescence imaging (Figure 4.7) and qRT-PCR (Figure 4.8). The samples were 
evaluated at 3 different time points; before differentiation, early differentiation, and terminal 
differentiation. The immunofluorescence images of the myotubes stained for myosin heavy chain 
(MF20) showed that myotubes formed without rGO showed MF20 expression from early 
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differentiation stage (Figure 4.7 A, first row). On the other hand, MF20 expression was visible on 
rGO-treated C2C12 group before differentiation (Figure 4.7 A, second row). The C2C12 
myoblasts were stained with F-actin and α-Actinin to observe the attachment on the substrate and 
confirm that the differentiated myotubes are mature (Figure 4.7 B).  
Before differentiation, the C2C12 myoblasts treated with and without rGO showed only 
F-actin expression. During early differentiation stage, the myotubes showed striation and the F-
actin morphology became elongated. The maturity and differentiation level were confirmed again 
with qRT-PCR (Figure 4.8). We compared different myogenic markers at different time points 
using desmin (DES), myostatin (MSTN), myogenic factor 5 (MYF5), myogenic factor 5 (MYF5), 
myoblast determination protein (MYOD), myogenin (MYOG), troponin I (TNNI), and myosin 
heavy chain 1 (MHC1). These markers include early stage myogenic markers (DES, MYF5, and 
MYOD), mid stage differentiation marker (MYOG), and late stage differentiation marker (MYH1). 
As a result, MYF5 (1.38-fold change), MYOD (1.36-fold change), and MYH1 (1.31-fold change) 
showed significant increase on day 3 upon rGO treatment. Other markers showed slight increase 
in expression level. On day 7, MYOD (1.30-fold change) and MYOG (1.37-fold change) showed 
significant increase in mRNA expression level. Although the MYH1 expression was slightly 
decreased, there was no statistical significance. Lastly, on day 14, MYF5 and MYOD showed 
1.24-fold change and 1.47-fold change, respectively. 
According to the immunofluorescence images, the rGO-treated C2C12 myoblasts showed 
myosin heavy chain expression on day 3. However, we could not observe the striated myotubes. 
This result addresses that the presence of rGO facilitates myogenic differentiation in early stage 
but the myotubes need more time to become mature myotubes. In addition, since rGO enhanced 
connexin 43 expression at early differentiation stage, higher expression of the connexin 43 protein 
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could have caused the cells to differentiate more actively.  
In fact, upregulated connexin 43 expression during myogenic differentiation causes 
myoblasts to communicate with adjacent cells faster.22 Therefore, it can be interpreted that 
enhanced connexin 43 expression due to rGO treatment promotes active intercommunication 
between the myoblasts. This event could have resulted in detection of the MHC marker at early 
differentiation stage. Furthermore, myotubes formed with rGO-treated C2C12 myoblasts showed 
higher DES, MYF5, MYOD, MYOG, TNN1, and MYH1 expression. These markers play a 
significant role during myogenesis and myogenic differentiation.31  
 
4.2.4 Genetic Changes in C2C12 Myoblasts after rGO Treatment 
We further explored the genetic changes that occurred in C2C12 myoblasts when rGO 
was present. The cells treated with and without rGO were collected at before differentiation and 
terminal differentiation stage. We made 5 contrasts for testing the effects of rGO treatment, the 
effect of time, and lastly the interaction (i.e. the time effect in rGO group vs the time effect in 
control group) (Table 4.1). First of all, comparison between the time periods generated more 
differentially expressed genes than the treatment itself. More number of differentially expressed 
genes were present when we compared before and terminal differentiation stages, both in C2C12 
and rGO-treated C2C12 groups. Total number of 10,833 differentially expressed genes were 
detected with C2C12 cells, and 11,774 with rGO-treated C2C12 cells. The myoblasts cultured with 
rGO, however, showed a greater number of differentially expressed gene at terminal differentiation 
stage. Comparison between the C2C12 and rGO-treated C2C12 cells only showed 160 




 Based on the interaction result, we compared the total of 7,474 differentially expressed 
genes with p < 0.05 value and plotted those genes on a heatmap (Figure 4.9). The color key shows 
if the gene was relatively upregulated (red) or downregulated (blue). We specifically tracked gap 
junction related genes among the differentially expressed genes (Figure 4.10). Three genes were 
found including Gja1 (connexin 43), Gjd4 (connexin 39), and Gjb3 (connexin 31). As a result, 
connexin 43 expression significantly decreased after myogenesis in both groups. The extent of 
downregulation, however, was much greater without rGO treatment. Connexin 39 is also known 
to be expressed during muscle embryonic development and fusion.32, 33 The expression of connexin 
39 was enhanced further when rGO was present in culture. Connexin 31, not known to be 
expressed in skeletal muscle, was downregulated upon rGO treatment.34  
Genes that directly regulates myogenic differentiation, myogenesis, and muscle 
regeneration were plotted in two different ways; to show the time effect in presence of rGO and to 
show the rGO effect at different time points (Figure 4.11). Among the genes that directly regulates 
myogenic differentiation, myogenesis and muscle regeneration, 17 genes were upregulated with 
respect to time in C2C12 myoblasts (red bar graph in Figure 4.11 A) and the presence of rGO 
further upregulated expression of 11 genes among the 17 genes (blue bar graph in Figure 4.11 A). 
Furthermore, 9 genes were downregulated further in rGO-treated C2C12 group among the 17 
downregulated genes in C2C12 myoblasts. We additionally compared how treatment of rGO 
change these gene expression at different time points (Figure 4.11 B). As a result, we observed 
early myogenic markers upregulated at before differentiation time point (grey bar graph in Figure 
4.11 B) while these markers were downregulated at terminal differentiation time point (black bar 
graph in Figure 4.11 B). The results were opposite for terminal differentiation markers. The 
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terminal differentiation markers were upregulated at terminal differentiation stage and 
downregulated at before differentiation stage. 
Next, we plotted the negative regulators of myogenic differentiation, myogenesis and 
muscle regeneration. We first tracked the gene expression change with respect to time (Figure 
4.12). As a result, 4 out of 7 negatively regulators were downregulated when rGO was present 
during myogenic differentiation (Figure 4.12 A). As we compared how rGO influenced the gene 
expression change at different time points, 5 genes were downregulated both at before and terminal 
differentiation stages in presence of rGO (Figure 4.12 B). 
Lastly, we plotted other genes that also relates to muscle development and function 
(Figure 4.13). The presence of rGO during differentiation further upregulated 5 genes (Figure 4.13 
A). Specifically, the troponin subunits, troponin C, troponin T3, troponin I were upregulated 
further compared to C2C12 myoblasts. Interestingly, troponin T2 which plays role in cardiac 
muscle contraction was downregulated. Other skeletal muscle related gene expressions including 
actin, and GTP binding protein expressions were upregulated. We also compared these gene 
expression levels at different time points to examine the effect of rGO (Figure 4.13 B). The 
troponin expression were especially upregulated at terminal differentiation stage. 
The number of differentially expressed genes show how the presence of rGO contributes 
to myogenic differentiation and myogenesis over time. During myogenic differentiation, multiple 
signaling pathways change in response to fusion and development.35-37 The presence of rGO at 
early stage of differentiation does not show significant gene expression changes but the promotes 
genetic changes at terminal differentiation stage. Thus, it can be concluded that rGO in skeletal 
myoblasts can facilitate myogenesis during fusion and dramatically change the gene expression 
levels after forming myotubes. The mechanism of how rGO triggered certain myogenic genes, 
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however, should be investigated further. 
 
4.2.5 Decoupling the Conductivity of rGO and Enhancement in Connexin 43 Expression Level 
 We validated if conductivity of the rGO is enhancing the contraction of muscles under 
electrical stimuli. We used Channel rhodopsin transfected C2C12 cells which express light-
sensitive ion channel. The differentiated myotubes respond to the 470 nm blue LED light and 
contract.10, 38 The myotubes with and without rGO were stimulated both optically and electrically 
to compare the displacement of the myotubes (Figure 4.14). When we electrically stimulated the 
myotubes, the displacement was 1.41-fold higher upon rGO treatment. However, the fold change 
was similar when the two groups were stimulated optically. Myotubes formed with C2C12 treated 
with rGO showed 1.51-fold higher displacement. The fold change in displacement upon different 
stimuli was also plotted. Both groups showed increased displacement when the cells were 
electrically stimulated. Interestingly, the fold change was almost the same showing 1.39-fold 
change in C2C12 group, and 1.31-fold change in rGO treated C2C12 group.  
 We decoupled the conductivity of rGO and its ability to enhance connexin 43 in myoblasts. 
The conductivity of the material did not influence the rGO-treated C2C12 group generate greater 
displacement. Thus, myotube differentiation is mainly a result of connexin 43 enhancement in 
myoblasts in presence of rGO. 
 
4.2.6 Enhanced Fluid Transport with Skeletal Muscle Treated with rGO 
 Because our results above revealed that myogenic factor expressions are upregulated when 
C2C12 myoblasts are treated with rGO, we sought to evaluate the functionality of the differentiated 
myotubes. Previously, we have developed a platform called “pump-bot,” capable of measuring 
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fluid flow.25 We first engineered myotubes in 3D muscle ring and placed the ring on a flexible 
polyacrylamide hydrogel tube. The tube was assembled to a closed microfluidics system fabricated 
with polydimethylsiloxane (PDMS). The chamber, where the hydrogel tube and muscle ring were 
placed, was stimulated electrically to stimulate the muscle to contract and induce fluid flow (Figure 
4.15). 
 First, the rGO treated muscle rings showed black color due to the color of the rGO itself 
(Figure 4.16 A, muscle ring in black dashed box). The muscle ring fabricated with C2C12 
myoblasts was white in color (Figure 4.16 A, muscle ring in red box). In order to compare the tube 
deformation caused by the muscle rings, we tracked the movement of the hydrogel tube using an 
image analysis software, Tracker. As we tracked the displacement, the movement caused by the 
rGO-treated muscle ring was as high as 73 µm (Figure 4.16 B). The displacement caused by the 
muscle ring without rGO, however, was up to 27 µm.  
Then, we analyzed the average flow velocity and the flow rate by tracking the trajectories 
of the fluorescence beads (Figure 4.17). We divided the inner part of the hydrogel tube to 16 
sections and tracked the movement of the fluorescent beads. The average velocity of the beads in 
each section was plotted on a graph (Figure 4.17 A). The flow profile over the cross section of the 
gel was parabolic. In addition, the flow rate was higher in rGO treated muscle rings. Based on this 
movement, the net flow rate of the control group was 8.5 µl/min while rGO treated muscle rings 
showed 22.5 µl/min (Figure 4.17 B). The net flow rate was 2.65-fold higher with the pump-bot 
assembled with rGO treated muscle rings. 
 As a result of enhanced myogenic differentiation due to increased connexin 43 expression 
in myoblasts, rGO-treated myotubes exhibited more active displacement of the hydrogel tubes 
compared to the control myotubes. From this result, we could confirm that muscle maturation and 
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contraction force can be enhanced by rGO treatment.  
 Troponin acts as a control switch that senses the cytosolic calcium increase and makes the 
striated muscle to contract and produce force.39, 40 The protein consists of 3 subunits, troponin C, 
troponin I and troponin T. We particularly have observed upregulation in troponin I, troponin T3, 
and troponin C upon treating rGO to the C2C12 myoblasts (Figure 4.13). Thus, upregulated 
troponin expression may have resulted in active contraction of the skeletal muscle rings and 
enhanced the force production. 
As we have seen our qRT-PCR results that C2C12 treated with rGO exhibited upregulated 
myogenic marker expression level (DES, MYF5, MYOD, MYOG, TNN1, and MYH1). It has been 
reported that upregulated expression of these markers contributes to increase in force production.38 
Thus, we expected skeletal muscles engineered in presence of rGO showed more displacement, 
generated more volumetric fluid flow and accelerated the fluid transfer in a pump-bot device. 
 
4.3 Conclusion 
The presence of rGO in C2C12 myoblasts promoted expression of connexin 43 in skeletal 
myoblasts and prolonged the expression time. In addition, the C2C12 myoblasts formed myotubes 
in early stage of differentiation, suggesting that presence of rGO shorten the time for the cells to 
fuse. As a result of enhanced and prolonged connexin 43 in C2C12 myoblasts, treatment of rGO 
supported enhancement of myogenic differentiation markers in the differentiated myotubes. This 
result was confirmed further with an RNA sequencing method. The rGO treated myotubes showed 
increased force production and induced faster fluid flow in a pump-bot system. We suggest further 
investigation should be performed to study how rGO is enhancing the myoblasts in a molecular 
level. This system may be useful to study the role of gap junction proteins in myotubes. Potentially, 
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the 3D muscle with rGO may be useful to build an in vitro skeletal muscle studying platform where 
we can characterize skeletal muscle related diseases or screen drugs to treat those diseases. 
 
4.4 Materials and Methods 
4.4.1 Characterization and analysis of rGO 
The rGO flakes used for the experiment was purchased from ACS Materials (ACS Material LLC). 
The rGO was characterized by Raman spectroscopy and Transmission electron microscopy (TEM). 
TEM analysis was performed using TEM (JEOL 2100 TEM). Based on the obtained TEM images, 
we measured the length and width of a single rGO sheet using image J software. 
 
4.4.2 Preparation of rGO for cellular assay 
A stock of 5 mg/ml rGO in 70% ethanol was prepared. The stock solution was pipetted well and 
sterilized under UV for 30 min. Then, the stock solution was vortexed at maximum speed for 10 
minutes and sonicated in a bath sonicator for an additional 30 minutes. The stock solution was 
diluted in growth medium at a concentration of 5 µg/ml. The C2C12 myoblasts, which reached 
80% confluency, was incubated with the rGO containing medium overnight at 37 °C. On the next 
day, the unattached rGO was removed and the cells that have rGO on the membrane were collected 
for further use.  
 
4.4.3 Cytotoxicity test of C2C12 myoblasts 
Tryphan blue exclusion assay was used to determine the number of viable cells in culture. The 
C2C12 myoblasts were treated with 0 µg/ml, 3 µg/ml, 5 µg/ml, and 10 µg/ml of rGO in growth 
medium. The cells were collected on day 1, 3, 7, and 10 and counted after treating with tryphan 
 
 74 
blue solution. Nine sections on the hemocytometer was counted, and total 4 culture samples were 
collected for single group on each day to verify the result.  
 
4.4.4 Immunocytochemical Analysis 
For both Connexin 43 staining and myotube staining, the samples were fixed in 4% (w/v) 
paraformaldehyde (Sigma) for 30 min, permeablized with 0.1% (v/v) Triton X-100 (Sigma) for 5 
min and incubated in blocking solution for 45 min at room temperature. After completing each 
step, the samples were washed with PBS 2 times. Post blocking, the samples were incubated in 
primary antibodies at 4 °C overnight. To stain for connexin 43, the samples were incubated in anti-
connexin43 (GJA1 antibody, Abcam). To stain for myogenic markers, another set of samples were 
rather incubated in MF-20 anti-MHC (1:400; iT FX, Developmental Studies Hybridoma Bank, 
The University of Iowa Department of Biology) or anti-sarcomeric a-actinin antibody (Abcam). 
On the next day, the samples were washed with PBS 2 times and connexin 43 was labeled with 
Alexa Fluor-488 donkey anti-rabbit IgG (1:500; Invitrogen). Samples incubated with MF-20 were 
labeled with Alexa Fluor-488 goat anti-mouse IgG (1:500; Invitrogen), and samples incubated 
with anti-sarcomeric a-actinin antibody were treated with Alexa Fluor-568 donkey anti-rabbit IgG 
(1:500; Invitrogen) as well as fluorescein (FITC)-conjugated Phalloidin. All samples were 
incubated in secondary antibodies for 1 hour. Finally, the nuclei were labeled with 4',6-Diamidino-
2-Phenylindole (DAPI, Sigma). The fluorescence images were obtained with a multiphoton 
confocal microscope (LSM 710, Carl Zeiss). 
 
4.4.5 Quantitative real-time polymerase chain reaction analysis 
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis conducted at 3 different 
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time points; before differentiation (day 3 after seeding), early differentiation (day 7 after seeding) 
and terminal differentiation (day 10 after seeding). Total RNA from the samples were extracted 
from C2C12 myoblasts by using RNeasy Mini Kit (Qiagen) following the manufacturer’s protocol. 
After extracting the mRNA, cDNA synthesis was performed with qScript cDNA Super Mix 
(Quanta Biosciences) from 100 ng of RNA and the reaction was performed according to the 
manufacturer’s protocol. Then, SsoFast EvaGreen Supermix (Bio-Rad) was added to the cDNA 
and primers and the mixtures were analyzed using CFX Connect Real-Time System (Bio-Rad). 
For the analysis, the cycle threshold (Ct) values were compared relative to the GAPDH and control 
samples.  
 
4.4.6 RNA sequencing analysis 
The RNA samples were prepared with TruSeq Stranded mRNA-seq Sample Prep kit (Illumina). 
Differential gene expression analysis was performed using the limma-trend method on the logCPM 
values. Total 5 contrasts were made for testing the following effects; Before differentiation vs 
Terminal differentiation in control group, before differentiation vs terminal differentiation in rGO 
group, rGO vs control group at before differentiation stage, rGO vs control group at terminal 
differentiation stage and the interaction to compare the time effect in rGO group vs time effect in 
control group. Multiple testing correction was done separately for each comparison using the False 
Discovery Rate (FDR) method. The differential expression was considered significant at FDR p-
value < 0.05. 
 
4.4.7 3D muscle ring formation for Pump-bot analysis 
C2C12 myoblasts were treated with 5µg/ml rGO as mentioned above. On the next day, the cells 
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were collected to form muscle rings. The cells were first trypsinized and suspended at a 
concentration of 1.0X107 cells/ml in a mixture composed of growth medium supplemented with 
30% v/v Matrigel (BD Biosciences), 4mg/ml fibrinogen (Sigma), 0.5 U/mg thrombin (Sigma). 
Each well in the PDMS ring mold was supplemented with 150 µl cell mixture and incubated in 
37 °C for 1 hour. After the cell mixture compacted, the muscle rings were immersed in growth 
medium. C2C12 myoblasts without rGO treatment were used to form control group muscle rings. 
 
4.4.8 Hydrogel tube preparation 
To fabricate the flexible hydrogel tube, 1mL of 40% w/v aqueous solution of acrylamide, 4 µl of 
2% w/v methylene bis-acrylamide, 10 μl of 10% w/v ammonium persulfate, and 2 μl of 
tetramethylene diamine was mixed together. The mixture was applied on a hallow glass mold and 
left in room temperature for 30 minutes until the gel was completely cured. Then, the glass mold 
was removed, and the gel was incubated in water overnight. The fabricated hydrogel tube was 4 
mm in outer diameter and 3mm in inner diameter. 
 
4.4.9 Pump-bot assembly and fluid flow measurement 
The muscle ring was placed on the fabricated hydrogel tube after being incubated in growth 
medium for 2 days (Figure 4.16). After the muscle ring was placed on the tube, the ring was 
incubated for another day in growth medium. On day 3 after the muscle ring was formed, the 
growth medium was exchanged with differentiation medium. The muscle-tube complex was 
incubated in differentiation medium for another 7 days. Finally, the muscle-tube complex was 
placed on the Pump-bot device. While we assembled the muscle-tube complex with the device, 
FITC tagged fluorescence beads (diameter = 1µm, BD Bioscience) were injected into the hydrogel 
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tube as well as the channel in the Pump-bot device. The assembled Pump-bot was imaged with 
Olympus IX81 inverted microscope (Olympus). While imaging, the samples were maintained with 
37ºC and 5% CO2 in an environmental chamber. To induce muscle contraction, we stimulated the 
muscle rings with bipolar electrical pulses (9V amplitude, 50 ms pulse width). 
 
4.4.10 Investigating conductivity of rGO 
We used Chennelrhodopsin transfected C2C12 skeletal myoblasts, which respond to the 470 nm 
blue LED light. The cells were treated with rGO overnight and plated on a tissue culture plate. 
After the cells were cultured in growth medium for 3 days and differentiation medium for 10 days, 
the cells were stimulated both optically and electrically. The muscle layer was optically stimulated 
with a 470 nm LED (Mightex Systems Inc) with 50 ms pulses of 1Hz frequcncy. Additionally, the 
muscle layer was stimulated electrically with a custom-built electrical stimulation unit. The 
biphasic electrical pulses of 20 V amplitude and 50 ms pulse width were applied to the muscle 
layer. All videos for the conductivity analysis was recorded with Olympus ix81 inverted 
microscope (Olympus). 
 
4.4.11 Statistical analysis 
The statistical analyses were performed using unpaired Student’s t-test with Graph Pad Prism 6.0 
(Graph Pad Software Inc). Statistical differences were considered significant at p-value smaller 
than 0.05. 
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4.5 Figures and Table 
 
Figure 4.1 Schematic Illustration of the Experimental Procedure. Procedure of Treating C2C12 
myoblasts with rGO. The cells are first incubated with rGO containing medium overnight in 37 °C. 
On the next day, the C2C12 myoblasts with rGO are collected and used for 2D or 3D culture. 
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Figure 4.2 Timeline of the experimental procedure.  After the C2C12 myoblasts are cultured on 
the flask, they are treated with 5µg/ml rGO in growth medium and incubated overnight. The cells 
are collected on the next day and prepared either for 2D or 3D culture. The growth medium is 
replaced with differentiation medium after the cells are cultured in growth medium for 3 days. 




Figure 4.3. Characterization of reduced graphene oxide. (A) Transmission electron microscopy 
images of the rGO flakes, and size of the flakes based on the images (n=15). (B) Raman spectra 
of the rGO.  
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Figure 4.4 Cellular viability of the C2C12 and rGO treated C2C12 myoblasts. The experiment 
was performed on day 1, 3, 5, 7, and 10 (n=4) with Tryphan Blue Assay. Different concentrations 
(3µg/mL, 5µg/mL, and 10µg/mL) of rGO was tested and plotted on the graph relative to the control 
group (* and ** represent the statistical significance between the values. *p < 0.01, **p < 0.05).
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Figure 4.5 Treatment of rGO to C2C12 Myoblasts. (A) Optical image of the C2C12 myoblast 
after rGO treatment. (B) The concentration of rGO per myotube area. The concentration of rGO 





Figure 4.6 Time dependent change of connexin 43 expression in skeletal myoblasts. (A) 
Immunofluorescence staining of the control C2C12 and rGO treated C2C12 with connexin 43 
(Cxn 43, green) and nucleus (DAPI, blue). (B) Quantification of relative connexin 43 mRNA 
expression level in rGO treated C2C12 myoblasts before differentiation (day 3), early 
differentiation (day 7), and late differentiation (day 14) (n=3, * and ** represent the statistical 





Figure 4.7 Myogenic differentiation of the C2C12 upon rGO addition. (A) Immunofluorescently 
stained myotubes formed with control C2C12 myoblasts and rGO treated C2C12 myoblasts 
stained for myosin heavy chain (MF20, green), and nuclei (DAPI, blue). The images were taken 
before differentiation (day 3), at early differentiation (day 7), and late differentiation (day 14). (B) 
Striated myotubes of the control C2C12 and rGO treated C2C12 with alpha actinin (α-actinin, 
green) and nucleus (DAPI, blue). 
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Figure 4.8 Relative myogenic marker expression at different time points. qRT-PCR analysis 
performed to show relative myogenic marker expression levels in rGO treated C2C12 myoblasts 
before differentiation (day 3), early differentiation (day 7), and late differentiation (day 14) (n=3, 




Figure 4.9 Changes in gene expression analyzed by RNA sequencing. Heat map showing the 
differentially expressed genes (total 7474 genes, p-value<0.05, n=4). The color key indicates the 




Figure 4.10 Gap junction related gene expression change in C2C12 and C2C12 treated with rGO. 
The effect of time and rGO treatment were plotted separately (FDR p-value<0.05). 
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Figure 4.11 Genes that positively regulates myogenesis, myogenic differentiation, and muscle 
regeneration. (A) was plotted with respect to time and (B) was plotted with respect to presence of 
rGO (FDR p-value<0.05). 
 89 
 
Figure 4.12 Genes that negatively regulates myogenesis, myogenic differentiation, and muscle 
regeneration. (A) was plotted with respect to time and (B) was plotted with respect to presence of 
rGO (FDR p-value<0.05). 
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Figure 4.13 Genes that contribute to muscle development and function, but indirectly related to 
myogenesis, myogenic differentiation, or muscle regeneration. (A) was plotted with respect to time 
and (B) was plotted with respect to presence of rGO (FDR p-value<0.05). 
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Figure 4.14 Displacement graph to show the effect of rGO. Channel rhodopsin transfected C2C12 
cells were used to decouple the effect of conductivity from enhancement of connexin 43 resulted 




Figure 4.15 Procedure of Pump-bot assembly. Once the C2C12 myoblasts compact on the PDMS 
ring mold, the muscle ring was removed and placed on the polyacrylamide hydrogel tube. The 
ring-tube construct was assembled with the Pump-bot device to measure the fluid flow. 
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Figure 4.16 Displacement of the muscle ring in a Pump-bot device. (A) Image of the Pump-bot 
device assembled with rGO treated muscle ring. Image in the red box shows muscle ring formed 
with C2C12 without rGO treatment. (B)Representative deformation graph of the hydrogel tube.
 94 
 
Figure 4.17 Analysis of the fluid flow caused by muscle contraction. (A) Fluid flow profile 
plotted on graph. Each point represents the flow velocity at each position. (B) Representative net 




Table 4.1 The number of differentially expressed genes with FDR p-value < 0.05. The effect of 





(C2C12 vs rGO treated C2C12) 
Time Effect 











132 4769 5440 5887 3734 
Up 
Regulated 
28 4683 5393 5887 3740 
Not 
Significant 
13870 4578 3197 2256 6556 
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CHAPTER 5: THE ROLE OF CONNEXIN IN MYOGENIC DIFFERENTIATION OF 
SKELETAL MYOBLASTS 
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5.1 Introduction 
Gap junction is a cluster of an intercellular protein called connexin. This gap junction 
channel forms when the two hemichannels of the adjacent cells interact. By this direct 
communication between the cells, the cells can mediate exchange of molecules, metabolites, waste 
products, and electrical signals.1 Different types of connexin proteins exist and each protein is 
named after the molecular weight of the connexin. During skeletal muscle development, the 
myoblasts proliferate and fuse together to form multinucleated myotubes. Usually, the gap 
junctions play crucial role during this stage. Balogh et al., have reported that the connexin 43 
protein expression was upregulated in myoblasts but the expression level decreased after myotube 
formation.2 In addition, when gap junctions were blocked, myoblast fusion was inhibited and the 
myotubes were not formed properly.3, 4 Thus, the results have suggested that the presence of gap 
junctions is essential during myogenesis. Furthermore, Suzuki et al., showed in their paper that 
myoblasts that overexpressed connexin 43 differentiated into myotubes better.5 Previous studies 
have shown that skeletal myoblasts naturally express connexin 39, 40, 43, and 45 during 
myogenesis.6-8 The connexin 43 and connexin 45 particularly facilitate myogenic differentiation 
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induced by extracellular ATP.9 Furthermore, connexin 43 and 45 are found in skeletal muscle of 
the adult mice during regeneration. The connexin 39 and 40 proteins are expressed in embryos but 
disappear in adult mice muscle. The role of the gap junction proteins, however, are still not well 
understood. 
Gene transfection is a powerful tool to investigate functions of genes and observe the 
cellular products that results from that genetic activity. With this technology, desired nucleic acids 
including DNA and RNA can be introduced to the cell. The main goal of transfection is to control 
the gene expression in cells, either by enhancement or inhibition, and produce recombinant 
proteins.10 Since the role of connexin in skeletal muscle is still unclear, transfection has been used 
in muscle myogenesis studies to investigate the role of connexin in skeletal muscle. Suzuki et al., 
have reported that overexpression of connexin 43 in skeletal myoblasts enhances myogenic 
differentiation and intercellular communication between adjacent cells.5 In another study, the 
C2C12 cells were transfected to express connexin 43 after the myotubes are formed.11 When the 
myotubes expressing connexin 43 was grafted into the nude mouse hearts, the myotubes and host 
cardiomyocytes formed connexin 43 positive junctions. 
Here, we hypothesize that expression of the gap junction protein during myogenic 
differentiation facilitates differentiation of the skeletal myoblasts, thereby, promotes mature 
myotubes to form. In this study, we genetically modified the skeletal myoblasts to express 
connexin once myogenic differentiation initiates. We delivered connexin 37, 40, and 43 using a 
commercially available vector, lipofectamine 3000. Connexin 37 and 40 populates in endothelial 
cells and form gap junctions between arteriolar endothelial cells, but this is not expressed in 
skeletal muscle.12 Reports have shown connexin 37 generates new blood vessels around the 
skeletal muscle and contributes to angiogenesis of the skeletal muscle during regeneration.12, 13 
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Connexin 40 is also found in cardiomyocytes and developing myoblasts and myotubes. 6 However, 
it is only expressed in early stage of the myogenic differentiation particularly at the outer side 
where myoblasts fuse to form myotubes. Connexin 43 are known to be involved in skeletal muscle 
fusion and differentiation.5, 13, 14 We differentiated C2C12 myoblasts without transfection (C2C12) 
and C2C12 myoblasts transfected with connexin 37 (C2C12-Cx37), connexin 40 (C2C12-Cx40), 
and connexin 43 (C2C12-Cx43) to explore how different connexin proteins influence myogenic 
differentiation. To examine this, we compared the morphology, creatine kinase activity, 
proliferation, and myogenic differentiation. We selected 3 different time points; day 2(before 
differentiation), day 4, (early differentiation) and day 8 (terminal differentiation) (Figure 1).  
 
5.2 Results and Discussion 
5.2.1 Connexin Expression in Undifferentiated Myoblasts and Differentiated Myotubes 
 We investigated if the presence of connexin protein is retained after myogenic 
differentiation in the transfected cells by qRT-PCR and immunofluorescence imaging (Figure 2-
4). We performed qRT-PCR at different time points to examine the time when connexin was 
expressed in the C2C12 cells, and to confirm that each transfected cell line expressed the delivered 
gene after differentiation was initiated (Figure 2). From day 2, difference was observable between 
groups (Figure 2A). Compared to the control group, C2C12-Cx37 expressed higher level of 
connexin 37. Similar result was observed with C2C12-Cx40 and C2C12-Cx43. It is also interesting 
to note that C2C12-Cx43 group showed elevated connexin 40 expression. On day 4, at early 
differentiation stage, relative gene expression was similar to day 2 (Figure 2B). Connexin 37 
expression level was elevated 120.64-fold compared to C2C12, C2C12-Cx40 and C2C12-Cx43 
groups. Similar result was observed with connexin 40 which showed 395.02-fold change compared 
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to the C2C12. Connexin 43 gene was expressed 3-fold higher in C2C12-Cx43 cells. In addition, 
the result was similar on day 8 (Figure 2C). Connexin 37 gene was expressed 197.324-fold higher 
in C2C12-Cx37 compared to C2C12, C2C12-Cx40, and C2C12-Cx43 cells. The expression of 
connexin 40 and connexin 43 was similar. Connexin 40 was expressed 226.86-fold higher in 
C2C12-Cx40 compared to the other three groups, and connexin 43 was expressed 2-fold higher in 
C2C12-Cx43 cells. Then, all samples were normalized to the same group in day 2 to track the 
expression change occurred within the same group (Figure 3A-D). In C2C12 group, all connexin 
expression levels were downregulated as differentiation occurred (Figure 3A). The transfected 
C2C12 myoblasts showed different result. The connexin 40 and connexin 43 expression level 
decreased in C2C12-Cx37 group on day 4 and day 8 (Figure 3B). The expression level of connexin 
37, however, was elevated on day 4, after myoblasts started fusion. Similarly, C2C12-Cx40 group 
showed elevated expression level of connexin 40 after differentiation (Figure 3C). The other 
connexin expression levels were downregulated compared to day 2. Lastly, C2C12-Cx43 group 
showed increased connexin 43 expression level while expression of connexin 37 and 40 were 
decreased compared to day 2 (Figure 3D). These results were confirmed with immunofluorescence 
images (Figure 4). When C2C12-Cx37 and C2C12-Cx40 were stained for connexin 40 on day 2, 
only C2C12-Cx40 cells showed fluorescence (Figure 4A). Connexin 43, however, were visible 
both in C2C12-Cx37 and C2C12-Cx40 groups on day 4 (Figure 4B). To investigate the expression 
of connexin 43 at different stages, we compared C2C12 with C2C12-Cx43 at different time points 
(Figure 4C). Connexin 43 expression was visible in both groups on day 2 and day 4. The expression 
level was higher on C2C12-Cx43 groups, as confirmed with qRT-PCR result. On day 8, connexin 
43 expression was only visible in C2C12-Cx43 group.  
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 The gap junction proteins are known to be downregulated after mature myotubes are 
formed. From the result, we could observe that wild type C2C12 cells showed decreased connexin 
37, 40 and 43 expression level from day 4. Furthermore, C2C12 group did not express connexins 
on day 8, when mature myotubes developed. It is interesting to note that the experimental groups 
showed upregulated connexin expression levels in myotubes. According to the results, we 
expected that the cells may be express different levels of myogenic factors at different time points. 
  
5.2.2 Effect of the Presence of Connexin in Myogenic Differentiation 
First, we confirmed that the myotubes formed on day 8 were mature myotubes. We 
fluorescently imaged the differentiated myotubes by labeling the myotubes with alpha actinin (α-
actinin), myosin heavy chain (MHC), and the nuclei (Figure 5A). The myotubes formed with 
C2C12, C2C12-Cx37, C2C12-Cx40, and C2C12-Cx43 cells were all striated and expressed 
myosin heavy chain on day 8. We also performed a morphometric analysis to compare the width 
and length of the myotubes (Figure 5B). The width of the myotubes formed with all 4 groups in 
the immunofluorescence images did not show much difference between the groups. The C2C12-
Cx43 group formed the myotubes with the greatest width (25.26 µm), followed by C2C12 
(21.85µm), C2C12-Cx40 (20.08 µm), and C2C12-Cx37 (19.99 µm). The length of the myotubes 
showed different tendency. The longest myotubes were formed with C2C12-Cx37 (1028.26 µm) 
followed by the myotubes formed by C2C12-Cx40 (1026.56 µm), C2C12-Cx43 (924.64 µm), and 
C2C12 (685.40 µm).  
Then, we further examined the extent of the myogenic differentiation at different time 
points (Figure 6). First, we determined the viability of the myotubes formed at different time points 
and measured the creatine kinase activity (Figure 6A). The myotubes formed with C2C12-Cx37, 
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C2C12-Cx40, and C2C12-Cx43 cells showed no relative change in viability compared to the 
control group. The muscle creatine kinase (MCK) activity, which shows the degree of myogenesis, 
was also measured on day 2, 4, and 8 (Figure 6B). Before Differentiation, the relative MCK activity 
decreased in C2C12-Cx37, C2C12-Cx40, and C2C12-Cx43 cells compared to the C2C12 cells. 
Once the myoblasts committed to differentiation, the relative fold change in the transfected cells 
increased. After day 8, the relative fold change remained high in C2C12-Cx37, and C2C12-Cx40 
groups. In C2C12-Cx43 group, the fold change decreased compared to the control group. 
To investigate the maturity of the myotubes, we performed qRT-PCR and compared the 
myogenic markers expressed at different time points (Figure 7, 8). We used 8 different markers 
for the experiment: desmin (DES), myostatin (MSTN), myogenic factor 5 (MYF5), myogenic 
factor 6 (MYF6), myosin heavy chain 1 (MYH1), MyoD, myobenin (MYOG), and troponin 1 
(TNN1). First, we normalized the relative mRNA expression of the myogenic markers expressed 
in the experimental group to C2C12 myoblasts on day 2, 4, and 8 (Figure 7). On day 2, C2C12-
Cx43 myoblasts showed the greatest number of myogenic markers increased compared to the 
C2C12 myoblasts (Figure 7A). Interestingly, MSTN, an inhibitory factor that blocks muscle 
growth and differentiation, was down regulated in all the experimental groups at all time points 
compared to the C2C12 group.15  
 On day 4, the difference between the control group and the experimental group became 
more dramatic. The myoblasts modified with connexin genes showed significant increase in early-
stage myogenic differentiation markers which includes DES, MYF5, and MYOD (Figure 7B). 
Additionally, MYOG, a mid-stage myogenic marker and terminal myogenic marker, MYF6 and 
TNN1, were significantly increased. Furthermore, MSTN expression was decreased in all the 
experimental groups. The expression of MSTN remained low in all the experimental groups. On 
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day 8, the myotubes in the experimental groups showed similar expression levels of the myogenic 
markers compared to the control group (Figure 7C). However, C2C12-Cx37 and C2C12-Cx43 still 
showed 1.46-fold and 1.32-fold increase in MYH1 expression level. In C2C12-Cx37, MYOG and 
TNN1 expression levels were also relatively higher than C2C12.   
 We further investigated the expression change within the group (Figure 8). Here, we 
normalized each group to the same group in day 2. On day 4, all of the experimental groups showed 
significant increase in MSTN, MYH1, MYOG, and TNN1 (Figure 8A). Interestingly, the early 
stage markers were increased in only the experimental groups. There was also a great increase in 
MYOG and TNN1 in C2C12-Cx40 group, showing 117.03-fold and 248.51-fold increase in 
expression levels. The difference in relative RNA expression levels were much greater on day 8 
(Figure 8B). The early-stage markers MYF5 and MYOD were decreased compared to day 2 in all 
groups. The expression of DES showed slight increase. The mid-stage and terminal stage markers 
were greatly increased in all groups. MYOG, was expressed 245-folds higher in C2C12-Cx40 
group on day 8 compared to day 2. The C2C12-Cx40 group also showed 871.88-fold increase in 
TNN1 expression level. 
As reported, connexin 40 and connexin 43 facilitates myogenic differentiation and 
myogenesis of the myoblasts and the expression is downregulated after mature myotubes are 
formed.6-8 Thus, during early differentiation, the overexpression of connexin 40 and connexin 43 
in the myoblasts may have aided myogenic differentiation to occur faster. Furthermore, the 
inhibitory factor MSTN remained low in all the experimental groups compared to the control group 
at all 3 timepoints. This indicates that presence of connexin in differentiating myoblasts, regardless 
of the type, suppresses the myogenesis inhibitory protein. Moreover, MSTN was downregulated 
in dramatically in C2C12-Cx40 and C2C12-Cx43 groups. This suggests that the presence of 
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connexin related to myogenic differentiation can suppress the inhibitory protein further. The 
MYOG being  
The C2C12-Cx37 cells also showed significant increase in myogenic markers and 
decrease in the inhibitory marker on day 4. Furthermore, myosin heavy chain 1 (MYH1), the 
protein that forms the muscle contractile unit to convert chemical energy to mechanical energy, 
and myogenin (MYOG), which helps muscle growth and regeneration, showed the greatest 
increase in fold change. Thus, this indicates that the presence of connexin, although not expressed 
in natural skeletal muscle, aids myogenic differentiation of the myoblasts.  
 
5.3 Conclusion 
 This study sought to discover the role of connexin 37, connexin 40, and connexin 43 
during myogenic differentiation. The C2C12 myoblasts were genetically modified to express 
connexin 37, connexin 40, and connexin 43 after differentiation initiated. In general, myoblasts 
naturally express connexin 40 and 43 during differentiation but the expression is downregulated 
once myotubes are formed. In contrary, connexin 37 is not expressed in skeletal muscle but are 
present in endothelial cells. In our results, the overexpression of connexin proteins, regardless of 
the type, facilitated myogenic differentiation. This event was noticeable particularly on early-stage 
differentiation, on day 4. All myogenic marker expression levels were increased, and the inhibitory 
marker expression level was decreased in C2C12-Cx37, C2C12-Cx40, and C2C12-Cx43 groups 
compared to the control C2C12 group. The increase in expression level compared to day 2 was the 
greatest in C2C12-Cx40 group on day 4 and day 8. Altogether, results of this study reveal the 
importance of the presence of connexin proteins during muscle development. For future study, the 
role of connexin in myotubes during muscle contraction can be further explored. These findings 
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could be useful to improve the function of the engineered muscle tissue used for drug screening or 
assembling a muscle-powered bio-actuators. 
 
5.4 Materials and Methods 
5.4.1 Transfection of C2C12 Myoblasts 
The C2C12 cell lines were made using a hyperactive piggyBac transposase-based, helper-
independent and self-inactivating delivery system, pmhyGENIE-3 containing a neomycin 
resistance gene for selection. The Cx43, Cx40, and Cx37 sequences were cloned downstream of 
the mouse MCK promoter cut from the pBS MCK promoter plasmid (Addgene plasmid # 12528; 
RRID:Addgene_12528). Constructed intermediate pENTR1A plasmid with a multiple cloning site 
followed by an IRES FusionRed from the plasmid FusionRed-pBAD (Addgene plasmid # 54677; 
RRID:Addgene_54677). The full MCK promoter +39nt (3389bp) was infused upstream of the 
MCS in pENTR1A MCS IRES FusionRed. Rat Cx37, Cx40, and Cx43 were infused 
afterwards. The resulting plasmids pENTR1A MCK Cx37 IRES FusionRed, pENTR1A MCK 
Cx40 IRES FusionRed, and pENTR1A MCK Cx43 IRES FusionRed were all LR recombined with 
the pmhyGENIE-3 containing a neomycin resistance gene in the backbone. Chief mCitrate from 
pcDNA3_1HChIEFmcit was added to pENTR1A intermediate clones by infusion upstream of 
MCK promoter.  All final plasmids along with a FusionRed only control and a ChIEF mCitrate 
control were transfected into C2C12 mouse myoblasts using lipofectamine 3000.  Cells were then 




5.4.2 Cell Culture 
C2C12 myoblasts were cultured in a cell culture flask in growth medium consisting of Dulbecco’s 
modified Eagle medium (DMEM, Corning) supplemented with 10% (v/v) fetal bovine serum (FBS, 
VWR), 1% (v/v) L-glutamine (Corning) and 1% (v/v) penicillin-streptomycin (PS, Corning). The 
cells were maintained in 37°C with 5% CO2. The cells were proliferated until they reach 70% 
confluency then collected for the experiments. After the cells were plated on a well plate for further 
analysis, the growth medium was replaced with differentiation medium on day 2 to induce 
myogenic differentiation. The differentiation medium was composed of DMEM supplemented 
with 10% (v/v) heat inactivated horse serum (Gibco), 1% (v/v) L-glutamine (Corning), 1% (v/v) 
PS (Corning), 50 ng/ml insulin-like growth factor-1 (IGF-1, Sigma Aldrich), and 1mg/mL 
aminocaproic acid (ACA, Sigma).  
 
5.4.3 Viability Assays 
Viability of the C2C12 myoblasts was quantified using a CellTiter 96 Aqueous One Solution (MTS, 
Promega) following the protocol provided by the manufacturer. The solution was mixed with 
DMEM without phenol red (LifeTechnologies) at a 5:1 (v/v) ratio. The cells were incubated in the 
mixture for 4 hours at 37°C and protected from light. Then, the absorbance was measured at 490nm 
using a plate reader (Synergy HT, BioTek). A blank solution without cells was subtracted from 




5.4.4 Muscle Creatine Kinase Assay 
The creatine kinase activity was determined by using a Liquid Creatine Kinase Reagent Set (Pointe 
Scientific) following the manufacturer’s instructions. First, the cells were trypsinized and collected. 
After removing all the supernatant, radioimmunoprecipitation assay (RIPA) buffer was added to 
the cell pellet. the samples were vortexed and rocked at 4°C for 30 min. The samples were, then, 
sonicated for 10 sec and centrifuged for 15 min at 14000 G. Lastly, 50 µl of the supernatant in the 
sample tube was mixed with 1 ml of working solution and transferred to a 96 well plate. The 
absorbance of the samples was measured at 340 nm with a plate reader. 
 
5.4.5 Immunofluorescence Staining 
All samples used for immunofluorescence staining were fixed in 4% (v/v) paraformaldehyde 
(Sigma) for 20 min, permeablized with 0.1% (v/v) Triton X-100 (Sigma) for 5 min and blocked 
with 2% (v/v) normal goat serum (Sigma) for 1 hour. Between each step, phosphate buffer saline 
(PBS) washing was performed 2 times. All procedures were conducted at room temperature. Then, 
the samples were treated with primary antibodies. To test correct expression of connexin 40 and 
connexin 43 in mature myoblasts, the cells were labeled with anti-connexin 40 (Thermo Fisher), 
and anti-connexin43 (1:1000) (GJA1 antibody, Abcam). To analyze the myogenic differentiation, 
the samples were incubated with MF-20 anti-MHC (1:400) (iT FX, Developmental Studies 
Hybridoma Bank, The University of Iowa Department of Biology), anti-sarcomeric α-actinin 
(1:400, Abcam) overnight at 4 °C. On the next day, the samples were rinsed with PBS 2 times and 
incubated with the secondary antibodies. Connexin 43 was labeled with Alexa Fluor-488 donkey 
anti-rabbit IgG (1:500; Invitrogen). MF-20 were labeled with Alexa Fluor-594 goat anti-mouse 
IgG (1:500; Invitrogen) and sarcomeric a-actinin antibody was treated with Alexa Fluor-594 
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donkey anti-rabbit IgG (1:500; Invitrogen). The samples treated with MF-20 antibody was also 
stained with fluorescein (FITC)-conjugated Phalloidin. After 1hour incubation at room 
temperature, the nuclei were labeled with 4',6-Diamidino-2-Phenylindole (DAPI, Sigma). The 
fluorescence images were obtained with a multiphoton confocal microscope (LSM 710, Carl Zeiss). 
 
5.4.6 Morphometric Analysis 
The morphometric analysis was performed by measuring the width, length, and fusion index based 
on the immunofluorescence images. Total number of 100 myotubes positively stained for MF-20 
was selected for the analysis. 
  
5.4.7 Statistical Analysis 
The statistical analyses in this study were performed based on unpaired Student’s t-test using a 
Graph Pad Prism 6.0 (Graph Pad Software Inc.) software. Results were considered significant 





Figure 5.1 Timeline for the experimental procedure. The experimental procedure plotted on a 
timeline. Cells before differentiation was analyzed on day 2. Growth medium was exchanged with 
differentiation medium on day 2 and analyzed on day 4 to examine early-stage differentiation. The 
cells cultured for 6 days in differentiation medium was analyzed for terminal differentiation. 
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Figure 5.2 qRT-PCR performed to examine the relative connexin expression at different time 
points. Connexin 37, connexin 40, and connexin 43 expression levels were examined on day 2 (A), 
day 4 (B), and day 8 (C). All samples were normalized to C2C12 on the same day (n=3, *p < 0.01 
vs C2C12, **p < 0.05 vs C2C12). The dashed line indicates 1 in the y-axis. The values below 1 
show relatively lower expression and the values above 1 show relatively higher expression of 




Figure 5.3 qRT-PCR result showing the change in connexin expression on day 4 and day 8 
compared to day 2. The samples on day 4 (A) and day 8 (B) were normalized to the same group 
on day 2 (n=3, *p < 0.01 vs same group on day 2, **p < 0.05 vs same group on day 2). The dashed 
line indicates 1 in the y-axis. The values below 1 show relatively lower expression and the values 




Figure 5.4 Immunofluorescence images of the myoblasts and myotubes stained for connexin 40 
and connexin 43. (A) C2C12-Cx37 and C2C12-Cx40 on day 4 (in early-stage differentiation) were 
stained for connexin 40 (Cx40, green) and nuclei (DAPI, blue). (B) C2C12-Cx37 and C2C12-
Cx40 on day 4 (in early-stage differentiation) stained for connexin 43 (Cx43, green), and nuclei 
(DAPI, blue). (C) C2C12 and C2C12-Cx43 on day 2, 4, and 8 stained for connexin 43 (Cx43, 
green), and nuclei (DAPI, blue). 
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Figure 5.5 Differentiated myotubes analyzed with immunofluorescence imaging and 
morphometric analysis on day 8. (A) Myotubes differentiated with C2C12, C2C12-Cx37, C2C12-
Cx40, and C2C12-Cx43 stained for α-actinin (red), myosin heavy chain (MHC, green), and nuclei 




Figure 5.6 Cellular viability and muscle creatine kinase analyses performed on day 2, day 4, and 
day 8. (A) Relative metabolic activity of C2C12, C2C12-Cx37, C2C12-Cx40, and C2C12-Cx43 
at different time points (n=4, *p < 0.05 vs C2C12). The samples were normalized to C2C12 sample 
on the same day. (B) Muscle creatine kinase fold change occurred in C2C12, C2C12-Cx37, 
C2C12-Cx40, and C2C12-Cx43 at different time points (n=4, **p < 0.01 vs C2C12, *p < 0.05 vs 





Figure 5.7 qRT-PCR performed to examine the relative myogenic markers at different time points 
normalized to C2C12. Early-stage markers (DES, MYF5, MYOD), mid-stage marker (MYOG), 
terminal stage markers (MYF6, MYH1, TNN1), and an inhibitory marker (MSTN1) expression 
levels were examined on day 2 (A), day 4 (B), and day 8 (C). All samples were normalized to 
C2C12 on the same day (n=3, *p < 0.01 vs C2C12, **p < 0.05 vs C2C12). The dashed line 
indicates 1 in the y-axis. The values below 1 show relatively lower expression and the values above 
1 show relatively higher expression of the myogenic markers compared to C2C12. 
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Figure 5.8 qRT-PCR performed to examine the relative myogenic markers on day 4 and day 8 
compared to day 2. The samples on day 4 (A) and day 8 (B) were normalized to the same group 
on day 2 (n=3, *p < 0.01 vs same group on day 2, **p < 0.05 vs same group on day 2). The dashed 
line indicates 1 in the y-axis. The values below 1 show relatively lower expression and the values 
above 1 show relatively higher expression of the myogenic markers compared to the same group 
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CHAPTER 6: CONCLUSION 
6.1 Summary 
 This thesis has described several approaches to improve the quality of engineered skeletal 
muscle in vitro. We recapitulated the optimal microenvironment for skeletal muscle development 
using physical, chemical and biological approaches. To recapitulate the physical characteristics of 
the skeletal muscle, a grooved topography that resembles the diameter of a myofibril was 
introduced to a polymer substrate. The linear topography anisotropically aligned the myotubes and 
promoted mature myotube formation. This also aided the co-cultured neural stem cells to 
differentiate into motor neuron progenitor cells and innervate into the myotubes to form a greater 
number of neuromuscular junctions. The engineered neuromuscular interface with mature 
myotubes showed active response to glutamate and curare. Also, the skeletal myoblasts were 
stimulated chemically by rGO treatment to enhance connexin 43 expression at early stage of 
differentiation and retain the expression level of connexin 43 at later stage of differentiation. The 
expression of connexin 43 proteins promoted myogenic differentiation both in gene and protein 
level. Furthermore, when rGO treated skeletal muscles were assembled into a pump-bot, the force 
generation and fluid flow through the device became greater compared the skeletal muscle tissue 
engineered with myoblasts without chemical stimulation. Lastly, myoblasts were genetically 
modified to express connexin proteins after differentiation was initiated. The differentiated 
myotubes engineered with genetically modified myoblasts as well as control myoblasts both 
showed mature and striated myotubes on terminal differentiation stage. However, the speed of 
differentiation was faster, and relative expression level of myogenic markers at terminal 
differentiation stage compared to the time before differentiation was significantly higher with the 
experimental group. The presence of connexin protein 37, 40, and 43 promoted the cells to express 
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myogenic markers at early-stage differentiation. Regardless of the type, the connexin protein 
facilitated this process. In addition, the myogenic differentiation gene expression level was 
significantly elevated in mid- and terminal stage when the myoblasts were genetically modified 
with connexin genes. 
  
6.2 Future Directions 
 The current work on engineering skeletal muscle tissue mainly focused on engineering 
skeletal muscle in vitro to present the possibility of engineering matured and functional tissue. 
Further work would need to focus on testing the engineered tissue as a potentially transplantable 
unit in an in vivo model or assembling a drug testing device with the functional tissue. The work 
on this thesis focused on the neural innervation to engineer a functional skeletal muscle tissue. In 
the natural skeletal muscle, the surrounding vasculature is also another significant factor that 
retains the health and function of the tissue. Future work should focus on investigating how to 
develop a co-culture system for endothelial cells and skeletal myoblasts for recapitulating the 
vascularization. In addition, uncovering the role of connexin protein in skeletal muscle function 
and force production would be needed.  
 
 
